Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1
value | Author stringclasses 1
value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
38000.0 | 2019-10-24 00:00:00 UTC | 3 Medical Marijuana Stocks to Buy | ACB | https://www.nasdaq.com/articles/3-medical-marijuana-stocks-to-buy-2019-10-24 | nan | nan | [Editor’s note: “3 Medical Marijuana Stocks to Buy” was previously published in September 2019. It has since been updated to include the most relevant information available.]
Often, when analysts or bloggers talk up the potential of , the focus is on the consumer side of the industry. But some of the best stocks in the... | ACB stock touched a seven-month low at the beginning of the month, and a rebound was undercut by a disappointing fiscal fourth-quarter report. Aurora Cannabis (ACB) Source: ElRoi / Shutterstock.com Like CRON stock, Aurora Cannabis (NYSE:) has a “falling knife” chart. Once profitability follows — which should be next ye... | Aurora Cannabis (ACB) Source: ElRoi / Shutterstock.com Like CRON stock, Aurora Cannabis (NYSE:) has a “falling knife” chart. ACB stock touched a seven-month low at the beginning of the month, and a rebound was undercut by a disappointing fiscal fourth-quarter report. Once profitability follows — which should be next ye... | Aurora Cannabis (ACB) Source: ElRoi / Shutterstock.com Like CRON stock, Aurora Cannabis (NYSE:) has a “falling knife” chart. ACB stock touched a seven-month low at the beginning of the month, and a rebound was undercut by a disappointing fiscal fourth-quarter report. Once profitability follows — which should be next ye... | Aurora Cannabis (ACB) Source: ElRoi / Shutterstock.com Like CRON stock, Aurora Cannabis (NYSE:) has a “falling knife” chart. ACB stock touched a seven-month low at the beginning of the month, and a rebound was undercut by a disappointing fiscal fourth-quarter report. Once profitability follows — which should be next ye... |
38001.0 | 2019-10-24 00:00:00 UTC | Short Sellers Continue to Pile Into These 4 Marijuana Stocks | ACB | https://www.nasdaq.com/articles/short-sellers-continue-to-pile-into-these-4-marijuana-stocks-2019-10-24 | nan | nan | For years, marijuana stocks could no wrong. But that's not the case any longer. Now that recreational pot is legalized in Canada, promises don't hold the clout they once did with Wall Street and investors. Rather, investors are looking for rapidly growing sales and an improvement in the bottom lines of all marijuana st... | The most widely held stock by the 6 million users of online app Robinhood, Aurora Cannabis (NYSE: ACB), continues to be a beacon for pessimists. Secondly, there's been a delay in getting derivative pot products to market, which pushed back when these higher-margin items would begin impacting the income statements of ma... | The most widely held stock by the 6 million users of online app Robinhood, Aurora Cannabis (NYSE: ACB), continues to be a beacon for pessimists. Over the same August-to-September time period listed previously for Aurora, pessimists increased their short shares held from 28.7 million to 31.7 million. Over the same one-m... | The most widely held stock by the 6 million users of online app Robinhood, Aurora Cannabis (NYSE: ACB), continues to be a beacon for pessimists. Over the same August-to-September time period listed previously for Aurora, pessimists increased their short shares held from 28.7 million to 31.7 million. Although HEXO is on... | The most widely held stock by the 6 million users of online app Robinhood, Aurora Cannabis (NYSE: ACB), continues to be a beacon for pessimists. Interestingly, though, short sellers haven't been adding to their positions in most marijuana stocks. Aurora Cannabis Surprise! |
38002.0 | 2019-10-23 00:00:00 UTC | Why Legalizing Marijuana Could Give the U.S. Economy a Big Boost | ACB | https://www.nasdaq.com/articles/why-legalizing-marijuana-could-give-the-u.s.-economy-a-big-boost-2019-10-23 | nan | nan | A lot of the talk on the markets these days is about a possible recession. Falling interest rates have raised concerns about how much longer the U.S. economy can keep going at its current pace. A big trade war with China doesn't help things, either.
However, one industry that could have a significant positive impact on... | CEO Terry Booth of Aurora Cannabis (NYSE: ACB) earns $380,000, while former Canopy Growth (NYSE: CGC) CEO Bruce Linton was earning $228,000 as of last year's data. That's a staggering amount of growth that could immediately provide people with jobs in an emerging industry and generate significant tax dollars. While the... | CEO Terry Booth of Aurora Cannabis (NYSE: ACB) earns $380,000, while former Canopy Growth (NYSE: CGC) CEO Bruce Linton was earning $228,000 as of last year's data. Job growth could be significant According to New Frontier Data, there are about 340,000 jobs in the U.S. legal pot market today. Why this is important for i... | CEO Terry Booth of Aurora Cannabis (NYSE: ACB) earns $380,000, while former Canopy Growth (NYSE: CGC) CEO Bruce Linton was earning $228,000 as of last year's data. Job growth could be significant According to New Frontier Data, there are about 340,000 jobs in the U.S. legal pot market today. The better Curaleaf and oth... | CEO Terry Booth of Aurora Cannabis (NYSE: ACB) earns $380,000, while former Canopy Growth (NYSE: CGC) CEO Bruce Linton was earning $228,000 as of last year's data. Job growth could be significant According to New Frontier Data, there are about 340,000 jobs in the U.S. legal pot market today. Even a bud trimmer can earn... |
38003.0 | 2019-10-23 00:00:00 UTC | Better Buy: Aphria vs. Constellation Brands | ACB | https://www.nasdaq.com/articles/better-buy%3A-aphria-vs.-constellation-brands-2019-10-23 | nan | nan | Some great news could be on the way for Aphria (NYSE: APHA) and Constellation Brands (NYSE: STZ). Both companies stand to win as the Canadian cannabis derivatives products hit the shelves in December. Aphria is gearing up to market a variety of products, while Constellation's big investment in Canopy Growth (NYSE: CGC)... | Interim CEO Irwin Simon confirmed in Aphria's fiscal 2019 Q4 conference call earlier this month that the company remains on track to deliver an annualized run rate of 1 billion in Canadian dollars in sales by the end of calendar year 2020. Canopy Growth is poised to be a big winner in the Canadian cannabis derivatives ... | Aphria is gearing up to market a variety of products, while Constellation's big investment in Canopy Growth (NYSE: CGC) means the alcoholic beverage maker will be closely watching the new Canadian market as well. The company ranks first in retail dollar sales growth among beverage alcohol suppliers, with Constellation ... | Aphria is gearing up to market a variety of products, while Constellation's big investment in Canopy Growth (NYSE: CGC) means the alcoholic beverage maker will be closely watching the new Canadian market as well. The company ranks first in retail dollar sales growth among beverage alcohol suppliers, with Constellation ... | Using the word "dominance" to describe Constellation's position in the U.S. premium beer market isn't an exaggeration. Canopy Growth is poised to be a big winner in the Canadian cannabis derivatives market, with plans to launch cannabis-infused beverages, edibles, and vape products. However, if I could only go with one... |
38004.0 | 2019-10-22 00:00:00 UTC | Aphria Stock Is Getting Into the Buy Zone | ACB | https://www.nasdaq.com/articles/aphria-stock-is-getting-into-the-buy-zone-2019-10-22 | nan | nan | With marijuana stocks in a grueling bear market, earnings season is definitely critical for the cannabis sector. So far, on the one hand, there was the terrible preliminary report from Hexo (NYSE:), which crushed the stock.
Source: Shutterstock
But there was a bright spot as well: Aphria (NYSE:). Last week, the company... | With marijuana stocks in a grueling bear market, earnings season is definitely critical for the cannabis sector. A key part of his strategy has been to focus on building a strong supply chain to lower the costs of production. The Bottom Line on Aphria Stock Importantly, Simon’s strategy of staying focused on profitabil... | In its last reported quarter, its revenues soared 849% year-over-year to CA$126.1 million and its EBITDA came in at $16.4 million, versus $1 million during the same period a year earlier. APHA’s guidance calls for fiscal 2020 full-year revenues to range from CA$650 million to CA$700 million and its adjusted EBITDA to b... | APHA’s guidance calls for fiscal 2020 full-year revenues to range from CA$650 million to CA$700 million and its adjusted EBITDA to be between CA$88 million and CA$95 million. The Bottom Line on Aphria Stock Importantly, Simon’s strategy of staying focused on profitability will prevent the company from coming under pres... | But APHA’s focus on profitability has not stunted its growth. Note that APHA is the third largest cannabis producer in Canada, behind Aurora Cannabis (NYSE:) and Canopy Growth (NYSE:). The Right Strategy Aphria stock has positive catalysts aside from the Canadian market. |
38005.0 | 2019-10-22 00:00:00 UTC | Mexico Unveiled Its Recreational Cannabis Bill: 8 Things You Need to Know | ACB | https://www.nasdaq.com/articles/mexico-unveiled-its-recreational-cannabis-bill%3A-8-things-you-need-to-know-2019-10-22 | nan | nan | Over the past two years, milestones and history have been made with regularity for the cannabis industry. Last year, for example, we witnessed Canada become the first industrialized country in the world to give the green light to recreational marijuana. Regulations concerning cannabis derivatives (e.g.'s edibles, infus... | Aurora Cannabis (NYSE: ACB), for example, acquired Farmacias Magistrales last December. As reported by Canamo Mexico and Marijuana Moment, the 74 article, 42-page draft is similar to a bill proposed last year by Interior Secretary Olga Sanchez Cordero, who was then serving as a senator. Although the first cannabis café... | Aurora Cannabis (NYSE: ACB), for example, acquired Farmacias Magistrales last December. Packaging regulations will be strict Also consistent with the message that's being sent throughout legalized North American markets, Mexico's recreational weed legislation calls for packaging to be nondescript, and for no real peopl... | Aurora Cannabis (NYSE: ACB), for example, acquired Farmacias Magistrales last December. The Cannabis Institute will oversee the Mexican pot industry Similar to the setup in Canada, a central agency, known as the Cannabis Institute, will be responsible for overseeing Mexico's marijuana industry. Mexico may have big mark... | Aurora Cannabis (NYSE: ACB), for example, acquired Farmacias Magistrales last December. Thus, recreational marijuana has already, in theory, been legalized by the Mexican Supreme Court. That makes the recreational market a less-than-stellar option for Aurora Cannabis and Medical Marijuana. |
38006.0 | 2019-10-22 00:00:00 UTC | Yikes! Will Canadian Pot Stocks Be Forced to Idle Their Grow Farms? | ACB | https://www.nasdaq.com/articles/yikes-will-canadian-pot-stocks-be-forced-to-idle-their-grow-farms-2019-10-22 | nan | nan | Roughly one year ago, the Canadian pot industry could do no wrong. Marijuana stocks in our neighbor to the north were near their all-time highs, and investors were content in the fact that Canada had just become the first industrialized country in the world to legalize recreational cannabis. Sales officially began on O... | With The Green Organic Dutchman admitting that demand will remain challenging in the near term, this should leave investors to wonder if capacity cuts or forced idling of existing facilities might be in the offing for Canada's other large growers, such as Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Canna... | With The Green Organic Dutchman admitting that demand will remain challenging in the near term, this should leave investors to wonder if capacity cuts or forced idling of existing facilities might be in the offing for Canada's other large growers, such as Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Howev... | With The Green Organic Dutchman admitting that demand will remain challenging in the near term, this should leave investors to wonder if capacity cuts or forced idling of existing facilities might be in the offing for Canada's other large growers, such as Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Regul... | With The Green Organic Dutchman admitting that demand will remain challenging in the near term, this should leave investors to wonder if capacity cuts or forced idling of existing facilities might be in the offing for Canada's other large growers, such as Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Regul... |
38007.0 | 2019-10-21 00:00:00 UTC | Marijuana Stock Canopy Growth to Expand in the U.K., Luxembourg | ACB | https://www.nasdaq.com/articles/marijuana-stock-canopy-growth-to-expand-in-the-u.k.-luxembourg-2019-10-21 | nan | nan | Much of the global cannabis industry's growth will occur in markets outside Canada and the U.S. Canopy Growth (NYSE: CGC) knows this, and the Canadian marijuana producer is rapidly expanding its international operations.
Canopy Growth announced on Monday that its Spectrum Therapeutics division has obtained licenses fr... | Only fellow cannabis titan Aurora Cannabis (NYSE: ACB), which has active operations in 25 countries, can claim to have more. "We are delighted to have been granted licenses from both the MHRA and Home Office in order to provide a solution to one of the most significant barriers for access in the U.K.," Spectrum managin... | Only fellow cannabis titan Aurora Cannabis (NYSE: ACB), which has active operations in 25 countries, can claim to have more. Canopy Growth announced on Monday that its Spectrum Therapeutics division has obtained licenses from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Home Office to store and di... | Only fellow cannabis titan Aurora Cannabis (NYSE: ACB), which has active operations in 25 countries, can claim to have more. Much of the global cannabis industry's growth will occur in markets outside Canada and the U.S. Canopy Growth (NYSE: CGC) knows this, and the Canadian marijuana producer is rapidly expanding its ... | Only fellow cannabis titan Aurora Cannabis (NYSE: ACB), which has active operations in 25 countries, can claim to have more. Much of the global cannabis industry's growth will occur in markets outside Canada and the U.S. Canopy Growth (NYSE: CGC) knows this, and the Canadian marijuana producer is rapidly expanding its ... |
38008.0 | 2019-10-21 00:00:00 UTC | The 65% Plunge in Aurora Cannabis Is Justified for These 5 Reasons | ACB | https://www.nasdaq.com/articles/the-65-plunge-in-aurora-cannabis-is-justified-for-these-5-reasons-2019-10-21 | nan | nan | As recently as March, marijuana stocks could do no wrong. Many, including the most popular pot stock in the world, Aurora Cannabis (NYSE: ACB), had logged triple- or quadruple-digit percentage gains over the previous three-plus years. These gains came on the back of some very lofty long-term sales projections from Wall... | Many, including the most popular pot stock in the world, Aurora Cannabis (NYSE: ACB), had logged triple- or quadruple-digit percentage gains over the previous three-plus years. Despite being forecast to lead all Canadian growers in peak annual output (possibly as much as 700,000 kilos per year, once all 15 facilities a... | Many, including the most popular pot stock in the world, Aurora Cannabis (NYSE: ACB), had logged triple- or quadruple-digit percentage gains over the previous three-plus years. When its Q4 report was actually released, Aurora produced an adjusted EBITDA loss of CA$11.7 million and looks to be nowhere near close to turn... | Many, including the most popular pot stock in the world, Aurora Cannabis (NYSE: ACB), had logged triple- or quadruple-digit percentage gains over the previous three-plus years. While practically all marijuana stocks have fallen victim to this retracement, it's been particularly noticeable for the most visible cannabis ... | Many, including the most popular pot stock in the world, Aurora Cannabis (NYSE: ACB), had logged triple- or quadruple-digit percentage gains over the previous three-plus years. These overseas markets are unlikely to become a real catalyst for Aurora until domestic demand in Canada is satisfied, and that could take nume... |
38009.0 | 2019-10-21 00:00:00 UTC | 1 Marijuana Stock That Could Deliver a Million-Dollar Payday | ACB | https://www.nasdaq.com/articles/1-marijuana-stock-that-could-deliver-a-million-dollar-payday-2019-10-21 | nan | nan | The legal marijuana industry has hit a crossroads. The inherent structural weaknesses in the Canadian market -- such as too few retail locations per province -- have wrecked havoc on quarterly earnings reports in the latter half of 2019, as well as earnings forecasts for 2020. These regulatory roadblocks, in turn, are ... | The big-picture issue is that the handful of names that survive the industry's rather volatile infancy should prove to be tremendous wealth generators for early-bird investors. It's quite possible, in fact, that the elite few left standing once the dust settles could transform an initial investment of $10,000 into a mi... | The legal marijuana industry has hit a crossroads. The crux is that Aphria may not be able to compete toe-to-toe against the likes of Aurora Cannabis or Canopy Growth if the Canadian cannabis market does begin to suffer from oversupply and international markets fail to open up quickly enough to absorb the overflow. Aft... | The crux is that Aphria may not be able to compete toe-to-toe against the likes of Aurora Cannabis or Canopy Growth if the Canadian cannabis market does begin to suffer from oversupply and international markets fail to open up quickly enough to absorb the overflow. 10 stocks we like better than OrganiGram Holdings When... | Here's what investors need to know. over Aphria. That's right -- they think these 10 stocks are even better buys. |
38010.0 | 2019-10-20 00:00:00 UTC | 3 Reasons Aurora Cannabis Could Soar Before the End of 2019 | ACB | https://www.nasdaq.com/articles/3-reasons-aurora-cannabis-could-soar-before-the-end-of-2019-2019-10-20 | nan | nan | Sure, Aurora Cannabis (NYSE: ACB) shares are down around 25% so far this year. And, yes, the stock is more than 60% off its highs set in the first quarter. But the growth prospects for the global cannabis industry still appear to be very good. Aurora remains a top candidate to prosper in thisglobal marketover the long ... | Sure, Aurora Cannabis (NYSE: ACB) shares are down around 25% so far this year. The company hired billionaire investor Nelson Peltz as a strategic advisor to help find one or more partners, especially within the consumer packaged goods industry. If early reports indicate that the launch of the Cannabis 2.0 market is goi... | Sure, Aurora Cannabis (NYSE: ACB) shares are down around 25% so far this year. If early reports indicate that the launch of the Cannabis 2.0 market is going a lot better than expected, it would boost many Canadian marijuana stocks, including Aurora. In Aurora's Q4 conference call, executives mentioned two specific reas... | Sure, Aurora Cannabis (NYSE: ACB) shares are down around 25% so far this year. In the company's Q4 conference call in September, CEO Terry Booth said that Aurora's "strategic partners are helping us talk to some of the top companies in the world" about the U.S. hemp cannabidiol opportunity. The Cannabis 2.0 market coul... | Sure, Aurora Cannabis (NYSE: ACB) shares are down around 25% so far this year. If early reports indicate that the launch of the Cannabis 2.0 market is going a lot better than expected, it would boost many Canadian marijuana stocks, including Aurora. In Aurora's Q4 conference call, executives mentioned two specific reas... |
38011.0 | 2019-10-18 00:00:00 UTC | Aurora Cannabis (ACB) Stock Is Poised to Rebound | ACB | https://www.nasdaq.com/articles/aurora-cannabis-acb-stock-is-poised-to-rebound-2019-10-18 | nan | nan | Aurora Cannabis (ACB) is well-positioned for the inevitable rebound in the cannabis sector, as it ramps up production capacity, boosts its GMP-compliant output, and develops a variety of derivative products to serve the Canadian and international markets.
By the end of June 2020, the company expects to have well over 6... | Aurora Cannabis (ACB) is well-positioned for the inevitable rebound in the cannabis sector, as it ramps up production capacity, boosts its GMP-compliant output, and develops a variety of derivative products to serve the Canadian and international markets. $5.30 price target In a very upbeat report, Jefferies analyst Ow... | Aurora Cannabis (ACB) is well-positioned for the inevitable rebound in the cannabis sector, as it ramps up production capacity, boosts its GMP-compliant output, and develops a variety of derivative products to serve the Canadian and international markets. $5.30 price target In a very upbeat report, Jefferies analyst Ow... | Aurora Cannabis (ACB) is well-positioned for the inevitable rebound in the cannabis sector, as it ramps up production capacity, boosts its GMP-compliant output, and develops a variety of derivative products to serve the Canadian and international markets. $5.30 price target In a very upbeat report, Jefferies analyst Ow... | Aurora Cannabis (ACB) is well-positioned for the inevitable rebound in the cannabis sector, as it ramps up production capacity, boosts its GMP-compliant output, and develops a variety of derivative products to serve the Canadian and international markets. $5.30 price target In a very upbeat report, Jefferies analyst Ow... |
38012.0 | 2019-10-18 00:00:00 UTC | Investors Beware: Tilray Stock Might Not Be Done Dropping | ACB | https://www.nasdaq.com/articles/investors-beware%3A-tilray-stock-might-not-be-done-dropping-2019-10-18 | nan | nan | Tilray (NASDAQ:), like other cannabis equities, continues to suffer from the effects of the bursting stock bubble. Tilray stock traded as high as $300 per share during the run-up in marijuana stocks, which preceded Canadian legalization in 2018. Since then, it has lost more than 92% of its value. This includes a nearly... | TLRY Could Recover — Eventually Despite a bleak outlook and a lack of profits, investors still have reasons to keep watching Tilray stock. However, getting to the point where rising revenues can finally yield profits will probably lead to actions that place more strain on both the balance sheet and TLRY. Sentiment has ... | Tilray (NASDAQ:), like other cannabis equities, continues to suffer from the effects of the bursting stock bubble. Also, once the dust settles, the company holds key assets and partnerships that could eventually take TLRY stock higher. My Final Thoughts on Tilray Stock Tilray stock will struggle to move higher without ... | Tilray stock traded as high as $300 per share during the run-up in marijuana stocks, which preceded Canadian legalization in 2018. TLRY Could Recover — Eventually Despite a bleak outlook and a lack of profits, investors still have reasons to keep watching Tilray stock. My Final Thoughts on Tilray Stock Tilray stock wil... | Sector Selloff Hits TLRY Stock TLRY trades at just over $22 per share. Moreover, its partnerships and assets could eventually help TLRY. This bodes well for continuing revenue growth. |
38013.0 | 2019-10-18 00:00:00 UTC | Where Is the Rebound for Fallen Canopy Growth Stock? | ACB | https://www.nasdaq.com/articles/where-is-the-rebound-for-fallen-canopy-growth-stock-2019-10-18 | nan | nan | With almost another month more to go before its next quarterly earnings report, Canopy Growth (NYSE:) may keep trading at new lows. The company no longer has the benefit of speculators bidding blindly for cannabis stocks. Its last quarterly earnings report, posted on Aug. 14, missed analyst consensus estimates on earni... | Source: Shutterstock Before speculating on a Canopy stock price rebound, investors must first understand why the company is exciting. Add the CDC’s warnings for e-cigarette risks and suddenly Canopy’s reliance on so-called Cannabis 2.0 for growth is uncertain. But to get to that set revenue rate, the company needs to i... | With almost another month more to go before its next quarterly earnings report, Canopy Growth (NYSE:) may keep trading at new lows. Its last quarterly earnings report, posted on Aug. 14, missed analyst consensus estimates on earnings and revenue. Pressure on Gross Margins Canopy started retrofitting its facility rooms ... | Source: Shutterstock Before speculating on a Canopy stock price rebound, investors must first understand why the company is exciting. Canopy Growth’s Goals Canopy set a $1 billion revenue rate but is still short of that target. My Takeaway on CGC Canopy is a growth hope story that markets are unwilling to speculate on ... | Its last quarterly earnings report, posted on Aug. 14, missed analyst consensus estimates on earnings and revenue. Canopy is a multi-billion dollar company by market capitalization — and it is building a business for the next several years. Pressure on Gross Margins Canopy started retrofitting its facility rooms last y... |
38014.0 | 2019-10-17 00:00:00 UTC | 3 Things You Should Expect With Canada's Cannabis 2.0 Recreational Marijuana Market | ACB | https://www.nasdaq.com/articles/3-things-you-should-expect-with-canadas-cannabis-2.0-recreational-marijuana-market-2019-10 | nan | nan | Today's the day. Exactly 12 months after Canada's historic legalization of adult-use recreational marijuana went into effect, the country's next phase of the recreational market is now in place.
Canadian regulators took longer to develop regulations for cannabis derivative products, including cannabis-infused beverages... | Aurora Cannabis (NYSE: ACB) even opted not to move forward initially with these products. Chief Corporate Officer Cam Battley said in the company's fiscal 2019 Q3 conference call in May that Aurora is developing cannabis-infused beverages but "considering the anticipated relatively low market share of these products, w... | Aurora Cannabis (NYSE: ACB) even opted not to move forward initially with these products. Canadian regulators took longer to develop regulations for cannabis derivative products, including cannabis-infused beverages, edibles, and concentrates used in vaping, than it did for the cannabis leaf and oils products legalized... | Aurora Cannabis (NYSE: ACB) even opted not to move forward initially with these products. Canadian regulators took longer to develop regulations for cannabis derivative products, including cannabis-infused beverages, edibles, and concentrates used in vaping, than it did for the cannabis leaf and oils products legalized... | Aurora Cannabis (NYSE: ACB) even opted not to move forward initially with these products. Canadian regulators took longer to develop regulations for cannabis derivative products, including cannabis-infused beverages, edibles, and concentrates used in vaping, than it did for the cannabis leaf and oils products legalized... |
38015.0 | 2019-10-17 00:00:00 UTC | Cronos Australia Offers Little Help to Cronos Group Stock | ACB | https://www.nasdaq.com/articles/cronos-australia-offers-little-help-to-cronos-group-stock-2019-10-17 | nan | nan | A venture partially owned by Cronos Group (NASDAQ:) will list publicly in Australia. Cronos Australia, also backed by NewSouthern Capital, will . This could help Cronos Group long term as it seeks to boost its visibility outside of North America. However, any benefit to CRON stock will probably take a long time to come... | Other than in the , recreational weed remains illegal in the “Land Down Under.” Still, this deal gives Cronos a segue by which it could become the leading provider of medical cannabis in Australia. Analysts tend to associate CRON stock with Canada’s top players due to the investment from tobacco giant Altria (NYSE:). C... | Expect Few Near-Term Effects on CRON Stock While I think this venture helps Cronos Group, how it helps CRON stock remains unclear. Although Cronos Australia may help CRON long term, it does little to change the value proposition in the immediate future. The Bottom Line on Cronos Group Stock The Cronos Australia IPO cou... | Expect Few Near-Term Effects on CRON Stock While I think this venture helps Cronos Group, how it helps CRON stock remains unclear. The Bottom Line on Cronos Group Stock The Cronos Australia IPO could help the reputation of Cronos Group, but will not benefit Cronos Group stock, at least for now. For now, Cronos Australi... | However, any benefit to CRON stock will probably take a long time to come, if it appears at all. The Bottom Line on Cronos Group Stock The Cronos Australia IPO could help the reputation of Cronos Group, but will not benefit Cronos Group stock, at least for now. Cronos Australia could help Peace Naturals become the best... |
38016.0 | 2019-10-17 00:00:00 UTC | Cannabis 2.0 May Reignite Rally in Aurora Cannabis Stock | ACB | https://www.nasdaq.com/articles/cannabis-2.0-may-reignite-rally-in-aurora-cannabis-stock-2019-10-17 | nan | nan | When Hexo Corp (NYSE:) posted preliminary fourth-quarter and full-year 2019 results, it took Aurora Cannabis (NYSE:) stock down with it. Hexo said it expected lower product sell-through, spooking investors in cannabis stock. But if Hexo cannot meet its $400 million revenue target for next year, Aphrira (NYSE:) and Cano... | After ACB stock closed near 52-week lows last week, markets priced in the near-term cost of headwinds and potential demand slowdown ahead. ACB Stock 2020 Outlook Aurora expects retail infrastructure to expand in 2020. Investors cannot predict when the selling pressure on ACB stock will ease. | ACB Stock 2020 Outlook Aurora expects retail infrastructure to expand in 2020. After ACB stock closed near 52-week lows last week, markets priced in the near-term cost of headwinds and potential demand slowdown ahead. Investors cannot predict when the selling pressure on ACB stock will ease. | ACB Stock 2020 Outlook Aurora expects retail infrastructure to expand in 2020. After ACB stock closed near 52-week lows last week, markets priced in the near-term cost of headwinds and potential demand slowdown ahead. Investors cannot predict when the selling pressure on ACB stock will ease. | ACB Stock 2020 Outlook Aurora expects retail infrastructure to expand in 2020. After ACB stock closed near 52-week lows last week, markets priced in the near-term cost of headwinds and potential demand slowdown ahead. Investors cannot predict when the selling pressure on ACB stock will ease. |
38017.0 | 2019-10-17 00:00:00 UTC | Load up on CGC Stock Before the Disappointment Starts to Fade | ACB | https://www.nasdaq.com/articles/load-up-on-cgc-stock-before-the-disappointment-starts-to-fade-2019-10-17 | nan | nan | Not long ago, Canopy Growth (NYSE:) seemed like a sure thing. The company appeared headed for ultimate domination of one of the fastest-growing markets on earth and CGC stock was unstoppable.
Source: Jarretera / Shutterstock.com
So what could possibly go wrong? Well, quite a bit it turns out. The performance of CGC sto... | The company appeared headed for ultimate domination of one of the fastest-growing markets on earth and CGC stock was unstoppable. It not only takes huge amounts of capital but requires a maniacal focus on building a solid infrastructure. The cannabis market is clearly a long-term growth opportunity, especially as more ... | Some of the problems include disappointments with the earnings announcements as well as the sudden termination of its CEO. But unfortunately, for many cannabis companies including CGC, the management teams do not have much experience with scaling operations. Then there is the leverage from a set of top brands like Coro... | The company appeared headed for ultimate domination of one of the fastest-growing markets on earth and CGC stock was unstoppable. But unfortunately, for many cannabis companies including CGC, the management teams do not have much experience with scaling operations. Bottom Line on CGC Stock There is a potential near-ter... | Then there are the problems with black market activities, which have taken market share away from legitimate operators. Granted, STZ management is clearly disappointed in the performance of CGC stock, but this really a positive. The cannabis market is clearly a long-term growth opportunity, especially as more and more ... |
38018.0 | 2019-10-17 00:00:00 UTC | Is Aphria a Value Stock? | ACB | https://www.nasdaq.com/articles/is-aphria-a-value-stock-2019-10-17 | nan | nan | Aphria (NYSE: APHA) has been one of the few bright spots in the legal cannabis space in 2019. Earlier this week, the company posted its second straight profitable quarter, and it is showing definitive signs of transforming into one of the industry's most compelling growth stories.
Even so, Aphria hasn't been able to es... | Aphria's place in the pantheon of Canadian pot stocks Aphria's core fundamentals compare rather favorably when stacked up against its chief Canadian rivals Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) (see the table below). The sneaking suspicion on Wall... | Aphria's place in the pantheon of Canadian pot stocks Aphria's core fundamentals compare rather favorably when stacked up against its chief Canadian rivals Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) (see the table below). Please note that these revenue... | Aphria's place in the pantheon of Canadian pot stocks Aphria's core fundamentals compare rather favorably when stacked up against its chief Canadian rivals Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) (see the table below). Aphria also exited the most re... | Aphria's place in the pantheon of Canadian pot stocks Aphria's core fundamentals compare rather favorably when stacked up against its chief Canadian rivals Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) (see the table below). While the company's shares hav... |
38019.0 | 2019-10-16 00:00:00 UTC | 3 Cannabis Stocks Hit By Seaport Global Reset | ACB | https://www.nasdaq.com/articles/3-cannabis-stocks-hit-by-seaport-global-reset-2019-10-16 | nan | nan | As the Canadian cannabis market undergoes growing pains, the industry stocks have taken a beating. The majority of the stocks in the sector are down over 50% as industry demand remains weak due to a lack of retail stores and a mounting flood of supply pressuring prices.
Seaport Global analyst Brett Hundley recently res... | We’ve delved into these three cannabis companies poised to struggle from low demand in Canada primarily due to a lack of retail stores all the way into 2021: Aurora Cannabis (ACB) Hundley makes big hits to the expectations for Aurora Cannabis in FY20 and FY21. The majority of the stocks in the sector are down over 50% ... | We’ve delved into these three cannabis companies poised to struggle from low demand in Canada primarily due to a lack of retail stores all the way into 2021: Aurora Cannabis (ACB) Hundley makes big hits to the expectations for Aurora Cannabis in FY20 and FY21. All of the other stocks in his coverage have Neutral rating... | We’ve delved into these three cannabis companies poised to struggle from low demand in Canada primarily due to a lack of retail stores all the way into 2021: Aurora Cannabis (ACB) Hundley makes big hits to the expectations for Aurora Cannabis in FY20 and FY21. The stock still has a market valuation approaching $4 billi... | We’ve delved into these three cannabis companies poised to struggle from low demand in Canada primarily due to a lack of retail stores all the way into 2021: Aurora Cannabis (ACB) Hundley makes big hits to the expectations for Aurora Cannabis in FY20 and FY21. A major sign of his bearish view was the maintaining of a B... |
38020.0 | 2019-10-16 00:00:00 UTC | Wait for the Dust to Settle Before Buying Canopy Growth Stock | ACB | https://www.nasdaq.com/articles/wait-for-the-dust-to-settle-before-buying-canopy-growth-stock-2019-10-16 | nan | nan | Canopy Growth (NYSE:) stock has taken a big hit in the pot stock maelstrom. Shares are down more than 50% since July. But with the stock trading close to its 52-week low, is now an opportunity to enter a position? Like its peers Aurora Cannabis (NYSE:), Hexo (NYSE:) and Tilray (NASDAQ:), shares remain richly valued. De... | Jefferies’ Owen Bennett “the most expensive name across the cannabis space.” He believes CGC has “material potential,” but is concerned with short-term performance. While in the past I was bearish on Constellation’s “hidden takeover” of Canopy, I now believe this relationship provides stability during the current pot i... | Like its peers Aurora Cannabis (NYSE:), Hexo (NYSE:) and Tilray (NASDAQ:), shares remain richly valued. Canopy Growth Stock Remains Overvalued CGC stock continues to trade at a high enterprise value/sales valuation. Based on fiscal 2021 estimates for Canopy Growth ($858.2 million in revenue), CGC stock’s forward EV/sal... | Canopy Growth (NYSE:) stock has taken a big hit in the pot stock maelstrom. Canopy Growth Stock Remains Overvalued CGC stock continues to trade at a high enterprise value/sales valuation. Based on fiscal 2021 estimates for Canopy Growth ($858.2 million in revenue), CGC stock’s forward EV/sales is 7.2. | Recent News at CGC CGC is facing similar headwinds as its peer Canadian cannabis companies. Canopy Growth Stock Remains Overvalued CGC stock continues to trade at a high enterprise value/sales valuation. Based on fiscal 2021 estimates for Canopy Growth ($858.2 million in revenue), CGC stock’s forward EV/sales is 7.2. |
38021.0 | 2019-10-16 00:00:00 UTC | Better Marijuana Stock: Aurora Cannabis vs. Namaste Technologies | ACB | https://www.nasdaq.com/articles/better-marijuana-stock%3A-aurora-cannabis-vs.-namaste-technologies-2019-10-16 | nan | nan | Anyone who looks into investing in marijuana stocks will no doubt quickly learn about Aurora Cannabis (NYSE: ACB). It has the second-largest market cap among Canadian cannabis producers and is followed heavily in the media and by investors. Namaste Technologies (OTC: NXTTF) (TSXV: N), on the other hand, is a small prov... | Anyone who looks into investing in marijuana stocks will no doubt quickly learn about Aurora Cannabis (NYSE: ACB). Namaste Technologies (OTC: NXTTF) (TSXV: N), on the other hand, is a small provider of an online e-commerce platform for the cannabis industry and receives relatively little attention. But if the global me... | Anyone who looks into investing in marijuana stocks will no doubt quickly learn about Aurora Cannabis (NYSE: ACB). Namaste has signed up multiple Canadian licensed producers offering their products on its CannMart e-commerce platform. But while I think Aurora could have solid long-term growth prospects as the global ca... | Anyone who looks into investing in marijuana stocks will no doubt quickly learn about Aurora Cannabis (NYSE: ACB). The case for Aurora Cannabis Aurora Cannabis' multiyear string of acquisitions has put the company on track to boast the largest production capacity in the entire cannabis industry. Aurora is the leading m... | Anyone who looks into investing in marijuana stocks will no doubt quickly learn about Aurora Cannabis (NYSE: ACB). The company's future hinges on success in global medical cannabis markets. But while I think Aurora could have solid long-term growth prospects as the global cannabis market expands, I don't recommend buyi... |
38022.0 | 2019-10-16 00:00:00 UTC | Crown Aphria the New King of Canadian Marijuana Stocks After Its Blowout Q1 Results | ACB | https://www.nasdaq.com/articles/crown-aphria-the-new-king-of-canadian-marijuana-stocks-after-its-blowout-q1-results-2019 | nan | nan | It's time to crown a new king among Canadian marijuana stocks. Sure, Canopy Growth (NYSE: CGC) claims the largest market cap and the biggest equity partner. Aurora Cannabis (NYSE: ACB) has the biggest production capacity. But based on its latest quarterly results, there's a solid argument to be made that the new king o... | Aurora Cannabis (NYSE: ACB) has the biggest production capacity. Defying HEXO's hex Aphria's share price sank on Monday as investors appeared to worry about a big letdown with the company's Q1 results. More good news likely on the way Aphria delivered positive Q1 results despite a small fire at its Broken Coast facilit... | Aurora Cannabis (NYSE: ACB) has the biggest production capacity. The company reported Q1 net income of 16.4 million Canadian dollars, or CA$0.07 per share, up from CA$15.8 million, or CA$0.05 per share, in the previous quarter. The company's net revenue from recreational cannabis sales rose from CA$18.5 million in the ... | Aurora Cannabis (NYSE: ACB) has the biggest production capacity. The company reported Q1 net income of 16.4 million Canadian dollars, or CA$0.07 per share, up from CA$15.8 million, or CA$0.05 per share, in the previous quarter. Aphria, however, did fall a little short of analysts' revenue projection of CA$131 million, ... | Aurora Cannabis (NYSE: ACB) has the biggest production capacity. Beating expectations Both Aurora and Canopy Growth overpromised and underdelivered in their most recent quarterly updates. This revenue total was even lower than the revenue of CA$128.6 million reported in the previous quarter. |
38023.0 | 2019-10-15 00:00:00 UTC | Aurora Cannabis Stock: It’s Not Time to Throw in the Towel | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock%3A-its-not-time-to-throw-in-the-towel-2019-10-15 | nan | nan | Boom and bust cycles can easily last a few years. A classic case is the dot-com cycle, when lasted from 1998 to 2000, giving investors time to snag juicy returns.
But cannabis stocks have been different. Their boom-bust cycle only lasted a year or so. And it is far from clear if marijuana stocks have bottomed.
Source... | Besides a thriving consumer business, ACB also has an extensive medical operation, as it employs more than 40 highly educated researchers, and has conducted a long list of clinical trials and case studies. Granted, the chart of ACB stock is downright scary. While the valuation of ACB stock is still far from cheap, its ... | Granted, the chart of ACB stock is downright scary. While the valuation of ACB stock is still far from cheap, its growth remains particularly strong. The Pros of ACB Stock Aurora has operations across 25 countries on five continents. | The Cons of ACB Stock It’s true that ACB stock is facing a great deal of risk. Granted, the chart of ACB stock is downright scary. While the valuation of ACB stock is still far from cheap, its growth remains particularly strong. | Granted, the chart of ACB stock is downright scary. While the valuation of ACB stock is still far from cheap, its growth remains particularly strong. The Pros of ACB Stock Aurora has operations across 25 countries on five continents. |
38024.0 | 2019-10-15 00:00:00 UTC | Can Aurora Cannabis Stock Make You Rich? | ACB | https://www.nasdaq.com/articles/can-aurora-cannabis-stock-make-you-rich-2019-10-15 | nan | nan | When Aurora Cannabis' (NYSE: ACB) shares commenced trading on the New York Stock Exchange on Oct. 23, 2018, retail investors were absolutely giddy with optimism. Prior to this uplisting, the Canadian pot titan had already taken a quantum leap forward by acquiring rivals CanniMed Therapeutics and MedReleaf Corp., and se... | When Aurora Cannabis' (NYSE: ACB) shares commenced trading on the New York Stock Exchange on Oct. 23, 2018, retail investors were absolutely giddy with optimism. Prior to this uplisting, the Canadian pot titan had already taken a quantum leap forward by acquiring rivals CanniMed Therapeutics and MedReleaf Corp., and se... | When Aurora Cannabis' (NYSE: ACB) shares commenced trading on the New York Stock Exchange on Oct. 23, 2018, retail investors were absolutely giddy with optimism. Driving this point home, the legal cannabis industry is expected to generate no less than $200 billion a year in sales by the end of the next decade, which wo... | When Aurora Cannabis' (NYSE: ACB) shares commenced trading on the New York Stock Exchange on Oct. 23, 2018, retail investors were absolutely giddy with optimism. That being said, there are two fundamental issues at play that should give early bird investors reason to stay the course during this turbulent period -- and ... | When Aurora Cannabis' (NYSE: ACB) shares commenced trading on the New York Stock Exchange on Oct. 23, 2018, retail investors were absolutely giddy with optimism. Retail investors, in turn, were bidding up Aurora's shares in the first part of 2019 with the hopes of catching the next Amazon.com or Netflix in the early in... |
38025.0 | 2019-10-15 00:00:00 UTC | Cannabis Stocks Peaked 1 Year Ago Today, and It's Been a Disaster Ever Since | ACB | https://www.nasdaq.com/articles/cannabis-stocks-peaked-1-year-ago-today-and-its-been-a-disaster-ever-since-2019-10-15 | nan | nan | The marijuana industry is thought of as one of the fastest-growing investment opportunities on the planet. Between 2014 and 2018, global sales of legal weed more than tripled from $3.4 billion to $10.9 billion, and the State of the Legal Cannabis Markets report from Arcview Market Research and BDS Analytics calls for a... | Here's a rundown of the trailing performance of eight brand-name Canadian cannabis stocks since their closing price on Oct. 15: CannTrust Holdings (NYSE: CTST): Down 92% Tilray: Down 87% Aphria (NYSE: APHA): Down 69% Aurora Cannabis (NYSE: ACB): Down 68% Canopy Growth (NYSE: CGC): Down 66% HEXO (NYSE: HEXO): Down 63% O... | Here's a rundown of the trailing performance of eight brand-name Canadian cannabis stocks since their closing price on Oct. 15: CannTrust Holdings (NYSE: CTST): Down 92% Tilray: Down 87% Aphria (NYSE: APHA): Down 69% Aurora Cannabis (NYSE: ACB): Down 68% Canopy Growth (NYSE: CGC): Down 66% HEXO (NYSE: HEXO): Down 63% O... | Here's a rundown of the trailing performance of eight brand-name Canadian cannabis stocks since their closing price on Oct. 15: CannTrust Holdings (NYSE: CTST): Down 92% Tilray: Down 87% Aphria (NYSE: APHA): Down 69% Aurora Cannabis (NYSE: ACB): Down 68% Canopy Growth (NYSE: CGC): Down 66% HEXO (NYSE: HEXO): Down 63% O... | Here's a rundown of the trailing performance of eight brand-name Canadian cannabis stocks since their closing price on Oct. 15: CannTrust Holdings (NYSE: CTST): Down 92% Tilray: Down 87% Aphria (NYSE: APHA): Down 69% Aurora Cannabis (NYSE: ACB): Down 68% Canopy Growth (NYSE: CGC): Down 66% HEXO (NYSE: HEXO): Down 63% O... |
38026.0 | 2019-10-15 00:00:00 UTC | Forget Canopy Growth: Why 1 Top Analyst Likes Aphria and Aurora Cannabis Instead | ACB | https://www.nasdaq.com/articles/forget-canopy-growth%3A-why-1-top-analyst-likes-aphria-and-aurora-cannabis-instead-2019-10 | nan | nan | What started off as a great year for major Canadian marijuana stocks has turned into a dumpster fire. The stocks of all five of the biggest players in the Canadian cannabis industry are down by double-digit percentages year to date, with four of the five plunging 25% or more.
Analysts have taken to cutting price target... | But while he's bearish about Canopy, this top analyst still likes two of the big five: Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB). Jefferies analyst Owen Bennett, for example, slashed his price target for Canopy Growth (NYSE: CGC) by two-thirds and downgraded the stock to an underperform rating from hold. The ... | But while he's bearish about Canopy, this top analyst still likes two of the big five: Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB). Down on Canopy Growth Canopy Growth remains the biggest Canadian cannabis producer by market cap even though its stock has dropped more than 60% from the highs set earlier this yea... | But while he's bearish about Canopy, this top analyst still likes two of the big five: Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB). Down on Canopy Growth Canopy Growth remains the biggest Canadian cannabis producer by market cap even though its stock has dropped more than 60% from the highs set earlier this yea... | But while he's bearish about Canopy, this top analyst still likes two of the big five: Aphria (NYSE: APHA) and Aurora Cannabis (NYSE: ACB). Down on Canopy Growth Canopy Growth remains the biggest Canadian cannabis producer by market cap even though its stock has dropped more than 60% from the highs set earlier this yea... |
38027.0 | 2019-10-14 00:00:00 UTC | What Happened in the Stock Market Today | ACB | https://www.nasdaq.com/articles/what-happened-in-the-stock-market-today-2019-10-14 | nan | nan | Major benchmarks drifted between gains and losses on light volume Monday as investors looked forward to third-quarter earnings reports starting in earnest tomorrow. The Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) closed down modestly. Materials and utility stocks were particularly w... | Aa for individual stocks, one analyst cut his price target for Aurora Cannabis (NYSE: ACB), adding to woes for investors in the marijuana industry, and AECOM (NYSE: ACM) rose after announcing details of a spinoff. Major benchmarks drifted between gains and losses on light volume Monday as investors looked forward to th... | Aa for individual stocks, one analyst cut his price target for Aurora Cannabis (NYSE: ACB), adding to woes for investors in the marijuana industry, and AECOM (NYSE: ACM) rose after announcing details of a spinoff. Pricing concerns plague Canadian cannabis stocks Investors continue to sour on marijuana stocks as analyst... | Aa for individual stocks, one analyst cut his price target for Aurora Cannabis (NYSE: ACB), adding to woes for investors in the marijuana industry, and AECOM (NYSE: ACM) rose after announcing details of a spinoff. Pricing concerns plague Canadian cannabis stocks Investors continue to sour on marijuana stocks as analyst... | Aa for individual stocks, one analyst cut his price target for Aurora Cannabis (NYSE: ACB), adding to woes for investors in the marijuana industry, and AECOM (NYSE: ACM) rose after announcing details of a spinoff. Pricing concerns plague Canadian cannabis stocks Investors continue to sour on marijuana stocks as analyst... |
38028.0 | 2019-10-14 00:00:00 UTC | 3 Major Catalysts That Will Drive Aurora Cannabis (ACB) Stock | ACB | https://www.nasdaq.com/articles/3-major-catalysts-that-will-drive-aurora-cannabis-acb-stock-2019-10-14 | nan | nan | As the sell-off in the cannabis sector continues, questions on the long-term performance of Aurora Cannabis (ACB) have risen to the point the company is at times presented as a basket case.
While that's nowhere near to being true, it does point to the need to clarify what the long-term outlook for the company is, and w... | As the sell-off in the cannabis sector continues, questions on the long-term performance of Aurora Cannabis (ACB) have risen to the point the company is at times presented as a basket case. In this article we'll look at the three major catalysts that investors need to follow in order to make an informed decision on tak... | As the sell-off in the cannabis sector continues, questions on the long-term performance of Aurora Cannabis (ACB) have risen to the point the company is at times presented as a basket case. Production Capacity At the end of June 2020, Aurora is expected to have production capacity of well over 600,000 kilograms annuall... | As the sell-off in the cannabis sector continues, questions on the long-term performance of Aurora Cannabis (ACB) have risen to the point the company is at times presented as a basket case. The Three Catalysts The three major things to consider when researching Aurora Cannabis are the potential impact of derivatives on... | As the sell-off in the cannabis sector continues, questions on the long-term performance of Aurora Cannabis (ACB) have risen to the point the company is at times presented as a basket case. Since there have been so many delays in Canada concerning licensing of retail outlets, I'm starting to think it terms of the secon... |
38029.0 | 2019-10-14 00:00:00 UTC | Canopy Growth Stock Has Gone Up in Smoke | ACB | https://www.nasdaq.com/articles/canopy-growth-stock-has-gone-up-in-smoke-2019-10-14 | nan | nan | Last year, Wall Street investors could not get enough of cannabis stocks and Canopy Growth (NYSE:) was the cream of the crop. This is because it received a large $4.5 billion investment from Constellation Brands (NYSE:). But we have since seen since other mistakes in valuations like the one in WeWork that cast doubt ov... | Last year, Wall Street investors could not get enough of cannabis stocks and Canopy Growth (NYSE:) was the cream of the crop. The alternative would be for the bulls of CGC stock to get a miracle headline that would bring them back to levels from say six months ago. This is truly a hopium trade where if I buy the stock ... | Last year, Wall Street investors could not get enough of cannabis stocks and Canopy Growth (NYSE:) was the cream of the crop. CGC Stock Is Broken Technically, CGC stock is in free fall with a potential target of $16.50 per share. So this is a wake-up call for Constellation Brands’ assessment of its original Canopy Grow... | Last year, Wall Street investors could not get enough of cannabis stocks and Canopy Growth (NYSE:) was the cream of the crop. CGC Stock Is Broken Technically, CGC stock is in free fall with a potential target of $16.50 per share. The alternative would be for the bulls of CGC stock to get a miracle headline that would b... | CGC Stock Is Broken Technically, CGC stock is in free fall with a potential target of $16.50 per share. This is not to say that cannabis stocks are cheap by any means. The Bottom Line on Canopy Growth Some of the stock drop is self-inflicted from management headlines. |
38030.0 | 2019-10-14 00:00:00 UTC | Cannabis 2.0 Is Coming: Watch ACB Stock Very Closely | ACB | https://www.nasdaq.com/articles/cannabis-2.0-is-coming%3A-watch-acb-stock-very-closely-2019-10-14 | nan | nan | In case you didn’t get the memo, what’s popularly known as “Cannabis 2.0” is coming to Canada on Oct. 17 as the nation finally legalizes cannabis-infused beverages, edibles, vapes, and similar products. Owners of Aurora Cannabis (NYSE:) stock could potentially be sitting on a green-hued gold mine if the pot-stock secto... | Bennett reminds me of those Katy Perry lyrics: “You’re hot and you’re cold/You’re yes and you’re no.” In a way, though, I can understand the price-target cut, as the ACB stock price has recently dipped under the C$5 level, making C$14 perhaps a bit unrealistic even with Cannabis 2.0 coming up. One Analyst’s Mixed Messa... | One Analyst’s Mixed Messages on ACB Stock It’s funny how an analyst can run hot and cold on the same exact stock at the same exact time, and we’ve got a textbook example of this with Aurora stock. In particular, Jefferies analyst Owen Bennett ACB stock is “one of the best-placed to succeed on a global basis over the lo... | One Analyst’s Mixed Messages on ACB Stock It’s funny how an analyst can run hot and cold on the same exact stock at the same exact time, and we’ve got a textbook example of this with Aurora stock. The Takeaway on Aurora Stock Don’t let the Jeffries analyst’s mixed bag of expectations on ACB stock throw you for a loop; ... | The Takeaway on Aurora Stock Don’t let the Jeffries analyst’s mixed bag of expectations on ACB stock throw you for a loop; with an early move into the burgeoning edibles market and the green light from Health Canada, Aurora will flourish through Cannabis 2.0 and beyond. One Analyst’s Mixed Messages on ACB Stock It’s fu... |
38031.0 | 2019-10-13 00:00:00 UTC | Mexico May Be Just Weeks Away From Legalizing Marijuana | ACB | https://www.nasdaq.com/articles/mexico-may-be-just-weeks-away-from-legalizing-marijuana-2019-10-13 | nan | nan | Last year, we saw marijuana history made many times over. Canada became the first industrialized country in the world to legalize recreational marijuana nearly one year ago, while the U.S. Food and Drug Administration approved its very first cannabis-derived drug. The latter is a pretty big deal, considering that marij... | For example, in December, Aurora Cannabis (NYSE: ACB) agreed to acquire Farmacias Magistrales, the only company given a license to import raw materials containing greater than 1% tetrahydrocannabinol (THC), the cannabinoid that gets users high. Not everyone in Mexico's Senate is necessarily in favor of the idea of a br... | For example, in December, Aurora Cannabis (NYSE: ACB) agreed to acquire Farmacias Magistrales, the only company given a license to import raw materials containing greater than 1% tetrahydrocannabinol (THC), the cannabinoid that gets users high. In Mexico, when the Supreme Court reaches a similar verdict five times, it ... | For example, in December, Aurora Cannabis (NYSE: ACB) agreed to acquire Farmacias Magistrales, the only company given a license to import raw materials containing greater than 1% tetrahydrocannabinol (THC), the cannabinoid that gets users high. Recreational cannabis legalization may happen very soon in Mexico According... | For example, in December, Aurora Cannabis (NYSE: ACB) agreed to acquire Farmacias Magistrales, the only company given a license to import raw materials containing greater than 1% tetrahydrocannabinol (THC), the cannabinoid that gets users high. Recreational cannabis legalization may happen very soon in Mexico According... |
38032.0 | 2019-10-13 00:00:00 UTC | Can Organigram Holdings Double Your Money? | ACB | https://www.nasdaq.com/articles/can-organigram-holdings-double-your-money-2019-10-13 | nan | nan | The past several months have been tough for OrganiGram Holdings (NASDAQ: OGI) shareholders. The stock has tumbled around 64% since a peak it reached this May, but better days could be around the corner.
The stock popped recently in response to a rating upgrade from Ryan Tomkins at Jeffries. The investment bank analyst ... | For example, Aurora Cannabis (NYSE: ACB) reported an average yield of 35 to 65 grams per plant, which is awful. Reasons to buy Over the past year, it's become painfully clear that the Canadian market for licensed cannabis isn't large enough to support a handful of the country's largest producers. Reason to wait Compani... | For example, Aurora Cannabis (NYSE: ACB) reported an average yield of 35 to 65 grams per plant, which is awful. Despite the intense competition for a limited number of cannabis consumers, Organigram has consistently reported operating profits, at least on an adjusted basis. In fact, Organigram is the only big producer ... | For example, Aurora Cannabis (NYSE: ACB) reported an average yield of 35 to 65 grams per plant, which is awful. You're probably thinking that simply making ends meet isn't a big deal, but during the latest round of earnings reports, Organigram was one of just two Canadian producers to report an operating profit. Organi... | For example, Aurora Cannabis (NYSE: ACB) reported an average yield of 35 to 65 grams per plant, which is awful. You're probably thinking that simply making ends meet isn't a big deal, but during the latest round of earnings reports, Organigram was one of just two Canadian producers to report an operating profit. That's... |
38033.0 | 2019-10-13 00:00:00 UTC | 9 Words in HEXO's Latest Update That Could Spell Big Trouble for Aurora Cannabis and Canopy Growth | ACB | https://www.nasdaq.com/articles/9-words-in-hexos-latest-update-that-could-spell-big-trouble-for-aurora-cannabis-and-canopy | nan | nan | Coal miners used to carry canaries in cages with them into the mine tunnels. If there were any dangerous gases in the mine, the canary would die first and serve as a warning for the miners to seek safety. "Canary in the coal mine" eventually became an expression to refer to anything that provided an early warning of da... | Those nine words could spell big trouble for the two largest Canadian cannabis producers, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Here are the particularly troublesome nine words for Aurora and Canopy in HEXO's press release last week: "Early signs of pricing pressure are being felt nationally." Lee ... | Those nine words could spell big trouble for the two largest Canadian cannabis producers, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Why Aurora and Canopy should be concerned Both Aurora and Canopy noted lower average selling prices in their latest quarterly updates. Canopy Growth CFO Mike Lee responded... | Those nine words could spell big trouble for the two largest Canadian cannabis producers, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Why Aurora and Canopy should be concerned Both Aurora and Canopy noted lower average selling prices in their latest quarterly updates. If what HEXO has observed is just th... | Those nine words could spell big trouble for the two largest Canadian cannabis producers, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Those troublesome nine words HEXO mentioned multiple problems in its preliminary Q4 update. Why Aurora and Canopy should be concerned Both Aurora and Canopy noted lower av... |
38034.0 | 2019-10-11 00:00:00 UTC | ACB November 29th Options Begin Trading | ACB | https://www.nasdaq.com/articles/acb-november-29th-options-begin-trading-2019-10-11 | nan | nan | Investors in Aurora Cannabis Inc (Symbol: ACB) saw new options begin trading today, for the November 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACB options chain for the new November 29th contracts and identified one put and one call contract of particular interest.
The... | Of course, a lot of upside could potentially be left on the table if ACB shares really soar, which is why looking at the trailing twelve month trading history for Aurora Cannabis Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACB's trailing twelve month trading history, w... | Below is a chart showing ACB's trailing twelve month trading history, with the $5.00 strike highlighted in red: Considering the fact that the $5.00 strike represents an approximate 31% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibi... | Below is a chart showing ACB's trailing twelve month trading history, with the $5.00 strike highlighted in red: Considering the fact that the $5.00 strike represents an approximate 31% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibi... | At Stock Options Channel, our YieldBoost formula has looked up and down the ACB options chain for the new November 29th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACB's trailing twelve month trading history, with the $5.00 strike highlighted in red: Consideri... |
38035.0 | 2019-10-11 00:00:00 UTC | What to Know Before Investing in the ETFMG Cannabis ETF | ACB | https://www.nasdaq.com/articles/what-to-know-before-investing-in-the-etfmg-cannabis-etf-2019-10-11 | nan | nan | In 2019, marijuana stocks have been on a roller coaster ride. Until mid-March, cannabis investors enjoyed an uptrend. And many marijuana stocks have surged 100%+ in just a few weeks.
Source: Shutterstock
But since April, many of them have lost considerable value, driven by the sector’s general weakness and poor earnin... | Nonetheless, the diversification of the MJ ETF limits its volatility and declines while retaining exposure to the potential gains of the cannabis market. Two Other Stocks to Note in the MJ ETF A wide range of products are made from cannabis, including CBD oils, edibles, cannabis-infused beverages, and concentrates u... | Among the in the MJ ETF are Aurora Cannabis (NYSE:), Cronos Group (NASDAQ:), Canopy Growth (NYSE:), Tilray (NASDAQ:) and Green Organic Dutchman Holdings (OTCMKTS:). But the ETF will have difficulty outperforming several of its large holdings, such as Cronos Group, Aurora Cannabis and Canopy Growth. The Bottom Line on t... | Cannabis Companies in the MJ ETF The MJ ETF currently holds 38 stocks. I’d like to highlight one stock, GW Pharmaceuticals (NASDAQ:), in the MJ ETF that is quite different than the other marijuana stocks. The Bottom Line on the MJ ETF MJ ETF offers exposure to Canadian cannabis producers and a number of biotech firms. | Cannabis Companies in the MJ ETF The MJ ETF currently holds 38 stocks. In 2019, the MJ ETF is down over 20%. Investors who buy MJ ETF in the near-term should hold the ETF for several years. |
38036.0 | 2019-10-11 00:00:00 UTC | If You Can Stomach It, Hold Onto Aurora Cannabis Stock | ACB | https://www.nasdaq.com/articles/if-you-can-stomach-it-hold-onto-aurora-cannabis-stock-2019-10-11 | nan | nan | You don’t have to dig much to find reasons to avoid cannabis companies like Aurora Cannabis (NYSE:). Most prominently, you have the ugly volatility in ACB stock. Although shares performed well for the first calendar quarter, it’s been downhill since the beginning of May. And on the Oct. 10 session, the equity dropped a... | Most prominently, you have the ugly volatility in ACB stock. No doubt, this remains a major fundamental risk to ACB stock. Vaping Crisis Might Discount but Not Sink ACB Stock As ugly as this vaping epidemic is for Aurora Cannabis stock, I believe the biggest victim is the truth. | Vaping Crisis Might Discount but Not Sink ACB Stock As ugly as this vaping epidemic is for Aurora Cannabis stock, I believe the biggest victim is the truth. Most prominently, you have the ugly volatility in ACB stock. No doubt, this remains a major fundamental risk to ACB stock. | Vaping Crisis Might Discount but Not Sink ACB Stock As ugly as this vaping epidemic is for Aurora Cannabis stock, I believe the biggest victim is the truth. Most prominently, you have the ugly volatility in ACB stock. No doubt, this remains a major fundamental risk to ACB stock. | Vaping Crisis Might Discount but Not Sink ACB Stock As ugly as this vaping epidemic is for Aurora Cannabis stock, I believe the biggest victim is the truth. Most prominently, you have the ugly volatility in ACB stock. No doubt, this remains a major fundamental risk to ACB stock. |
38037.0 | 2019-10-11 00:00:00 UTC | The 1 Sentence From HEXO That Tanked the Entire Marijuana Industry | ACB | https://www.nasdaq.com/articles/the-1-sentence-from-hexo-that-tanked-the-entire-marijuana-industry-2019-10-11 | nan | nan | The cannabis industry has been a red-hot investment for years, with many early investors racking up triple- or quadruple-digit percentages if they had the wherewithal (and stomach) to hold on for the ride. Incredible growth projections, one of which calls for $200 billion in worldwide sales by the end of the next decad... | From major pot growers like Aurora Cannabis (NYSE: ACB) and Canopy Growth, which will be offering an array of vapes and/or infused beverages, to smaller growers, this delay in the launch of derivatives means waiting another one to two quarters before sales growth has any real shot of picking up for Canadian pot stocks.... | From major pot growers like Aurora Cannabis (NYSE: ACB) and Canopy Growth, which will be offering an array of vapes and/or infused beverages, to smaller growers, this delay in the launch of derivatives means waiting another one to two quarters before sales growth has any real shot of picking up for Canadian pot stocks.... | From major pot growers like Aurora Cannabis (NYSE: ACB) and Canopy Growth, which will be offering an array of vapes and/or infused beverages, to smaller growers, this delay in the launch of derivatives means waiting another one to two quarters before sales growth has any real shot of picking up for Canadian pot stocks.... | From major pot growers like Aurora Cannabis (NYSE: ACB) and Canopy Growth, which will be offering an array of vapes and/or infused beverages, to smaller growers, this delay in the launch of derivatives means waiting another one to two quarters before sales growth has any real shot of picking up for Canadian pot stocks.... |
38038.0 | 2019-10-11 00:00:00 UTC | Stock Market News: Marijuana Stocks Get Another Vote of No Confidence | ACB | https://www.nasdaq.com/articles/stock-market-news%3A-marijuana-stocks-get-another-vote-of-no-confidence-2019-10-11 | nan | nan | Investors have had their eyes on the trade negotiations between the U.S. and China for a long time, and on Friday morning, they liked what they saw. Signs that a planned meeting between President Donald Trump and high-level Chinese officials would actually take place gave market participants more optimism about the pro... | Although share prices for key players like Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) didn't have much of an immediate response, a lot will depend on how successful their business efforts are in the months to come. Signs that a planned meeting between President Donald Trump and high-level Chinese officia... | Although share prices for key players like Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) didn't have much of an immediate response, a lot will depend on how successful their business efforts are in the months to come. For Aurora Cannabis, Jefferies slashed its price target in half to just CA$7, equivalent t... | Although share prices for key players like Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) didn't have much of an immediate response, a lot will depend on how successful their business efforts are in the months to come. Coming off a long high Shares of Canopy Growth were trading a fraction of a percent lower ... | Although share prices for key players like Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) didn't have much of an immediate response, a lot will depend on how successful their business efforts are in the months to come. Investors have had their eyes on the trade negotiations between the U.S. and China for a l... |
38039.0 | 2019-10-11 00:00:00 UTC | Is Aurora Cannabis’ Growth Strategy Enough to Turn Around ACB Stock? | ACB | https://www.nasdaq.com/articles/is-aurora-cannabis-growth-strategy-enough-to-turn-around-acb-stock-2019-10-11 | nan | nan | Shareholders of Aurora Cannabis (NYSE:) have been very disappointed and this is not surprising. ACB stock once seemed to have a tremendous amount of potential, but things have not worked out very well and it has been losing a significant amount of money.
Source: ElRoi / Shutterstock.com
For , which ended in June, Auror... | ACB stock once seemed to have a tremendous amount of potential, but things have not worked out very well and it has been losing a significant amount of money. Because of these losses, it is not surprising that ACB stock has seen a significant decline. A Look at ACB stock ACB stock went into a freefall in mid-September ... | A Look at ACB stock ACB stock went into a freefall in mid-September after breaking support the $5.50 level. ACB stock once seemed to have a tremendous amount of potential, but things have not worked out very well and it has been losing a significant amount of money. Because of these losses, it is not surprising that AC... | A Look at ACB stock ACB stock went into a freefall in mid-September after breaking support the $5.50 level. ACB stock once seemed to have a tremendous amount of potential, but things have not worked out very well and it has been losing a significant amount of money. Because of these losses, it is not surprising that AC... | Because of these losses, it is not surprising that ACB stock has seen a significant decline. A Look at ACB stock ACB stock went into a freefall in mid-September after breaking support the $5.50 level. ACB stock once seemed to have a tremendous amount of potential, but things have not worked out very well and it has bee... |
38040.0 | 2019-10-11 00:00:00 UTC | Canadian Cannabis Companies Are Struggling; Here's Why They Could Be Headed Even Lower | ACB | https://www.nasdaq.com/articles/canadian-cannabis-companies-are-struggling-heres-why-they-could-be-headed-even-lower-2019 | nan | nan | About a year ago, Aurora Cannabis (NYSE: ACB) was trading as high as $12.52 a share, a sobering reminder for investors of how far the stock has fallen since then. Today, Aurora's stock is less than one-third of that price. But it isn't alone; since legalization took place in Canada last October, marijuana stocks have p... | About a year ago, Aurora Cannabis (NYSE: ACB) was trading as high as $12.52 a share, a sobering reminder for investors of how far the stock has fallen since then. Disappointing sales numbers could lead to further declines What drove the industry to the heights it reached last year was the promises of growth and all the... | About a year ago, Aurora Cannabis (NYSE: ACB) was trading as high as $12.52 a share, a sobering reminder for investors of how far the stock has fallen since then. The analysts see sales for cannabis producers reaching $2.2 billion Canadian dollars in 2020 and just CA$3.3 billion the year after that. This year, producer... | About a year ago, Aurora Cannabis (NYSE: ACB) was trading as high as $12.52 a share, a sobering reminder for investors of how far the stock has fallen since then. However, that's assuming sales will also continue to grow at a high rate, and according to analysts from the CIBC (Canadian Imperial Bank of Commerce) the sa... | About a year ago, Aurora Cannabis (NYSE: ACB) was trading as high as $12.52 a share, a sobering reminder for investors of how far the stock has fallen since then. However, with the Canadian market having an estimated market size of $5.2 billion in five years and the U.S. still being off limits (besides hemp), the oppor... |
38041.0 | 2019-10-10 00:00:00 UTC | CRON Stock Still a Falling Knife Without a Catalyst | ACB | https://www.nasdaq.com/articles/cron-stock-still-a-falling-knife-without-a-catalyst-2019-10-10 | nan | nan | The market seems to have decided that cannabis stocks like Cronos Group (NASDAQ:) were in a bubble. Pot stocks have been absolutely hammered for the last few months, and Cronos Group stock has been no exception. CRON stock has dropped nearly two-thirds from its 52-week high, and now trades at 2019 lows.
Source: Shutter... | With a chart that is a textbook ‘falling knife’ and profitability still years out, there’s not much reason to predict a bottom in CRON stock just yet. If the opportunity long-term still is intact, the play is to go with Canopy or Aurora, two companies who are aggressively going after multiple markets in the industry. B... | The market seems to have decided that cannabis stocks like Cronos Group (NASDAQ:) were in a bubble. And it highlights the near-term problem for Cronos Group stock. Because of its disinterest in developing production capacity, CRON stock screens poorly on both metrics (at least on a relative basis). | Pot stocks have been absolutely hammered for the last few months, and Cronos Group stock has been no exception. The best thesis I’ve come up with is that Cronos stock is the cannabis play for investors who believe cannabis plays are overvalued. The Problem With CRON Stock “Now, we understand that many investors are mod... | The Problem With CRON Stock “Now, we understand that many investors are modeling cannabis companies off of their production capacity. Any investor trying to time the bottom here in cannabis stocks has to believe that the sell-off has gone too far. Cronos Group’s cash balance gives the company time to execute its strate... |
38042.0 | 2019-10-10 00:00:00 UTC | 9 Critical Things to Watch in Marijuana Stocks | ACB | https://www.nasdaq.com/articles/9-critical-things-to-watch-in-marijuana-stocks-2019-10-10 | nan | nan | Technical analysis has a bad reputation. This isn’t surprising because most of the technical analysis of marijuana stocks that I see is not very good. Some is downright terrible.
Even worse, some analysts are proponents of bizarre techniques like Gann Theory or Elliot Waves. These methods are like the Loch Ness Monster... | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is a Canadian-based company that grows and sells medical marijuana, indoor cultivation systems and hemp-related food products. ACB stock was in a freefall, but after becoming oversold it has broken its downtrend and is consolidating. If ACB turns around and rallies, there i... | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is a Canadian-based company that grows and sells medical marijuana, indoor cultivation systems and hemp-related food products. ACB stock was in a freefall, but after becoming oversold it has broken its downtrend and is consolidating. If ACB turns around and rallies, there i... | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is a Canadian-based company that grows and sells medical marijuana, indoor cultivation systems and hemp-related food products. ACB stock was in a freefall, but after becoming oversold it has broken its downtrend and is consolidating. If ACB turns around and rallies, there i... | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is a Canadian-based company that grows and sells medical marijuana, indoor cultivation systems and hemp-related food products. ACB stock was in a freefall, but after becoming oversold it has broken its downtrend and is consolidating. If ACB turns around and rallies, there i... |
38043.0 | 2019-10-10 00:00:00 UTC | Why OrganiGram Shares Tumbled 13.6% Today | ACB | https://www.nasdaq.com/articles/why-organigram-shares-tumbled-13.6-today-2019-10-10 | nan | nan | What happened
After competitor HEXO (NYSE: HEXO) reported third-quarter financial results that fell shy of expectations -- forcing it to rescind its sales guidance for 2020 -- shares of OrganiGram Holdings (NASDAQ: OGI) lost 13.6% of their value on Thursday in sympathy.
So what
Only days after the surprise resignation ... | Earlier this year, Canopy Growth's (NYSE: CGC) CEO was shown the door because of higher-than-expected losses, and shares of Aurora Cannabis (NYSE: ACB) fell sharply after the company failed to deliver results as strong as it had previously guided for. So what Only days after the surprise resignation of its chief financ... | Earlier this year, Canopy Growth's (NYSE: CGC) CEO was shown the door because of higher-than-expected losses, and shares of Aurora Cannabis (NYSE: ACB) fell sharply after the company failed to deliver results as strong as it had previously guided for. What happened After competitor HEXO (NYSE: HEXO) reported third-quar... | Earlier this year, Canopy Growth's (NYSE: CGC) CEO was shown the door because of higher-than-expected losses, and shares of Aurora Cannabis (NYSE: ACB) fell sharply after the company failed to deliver results as strong as it had previously guided for. What happened After competitor HEXO (NYSE: HEXO) reported third-quar... | Earlier this year, Canopy Growth's (NYSE: CGC) CEO was shown the door because of higher-than-expected losses, and shares of Aurora Cannabis (NYSE: ACB) fell sharply after the company failed to deliver results as strong as it had previously guided for. What happened After competitor HEXO (NYSE: HEXO) reported third-quar... |
38044.0 | 2019-10-10 00:00:00 UTC | Why Aurora Cannabis and Canopy Growth Are Betting on Outdoor Cannabis Cultivation | ACB | https://www.nasdaq.com/articles/why-aurora-cannabis-and-canopy-growth-are-betting-on-outdoor-cannabis-cultivation-2019-10 | nan | nan | Every Canadian cannabis producer under the sun has frantically scrambled to increase production capacity over the last couple of years. That scramble typically involved investing in greenhouses or artificially lighted indoor facilities capable of harvesting sizable cannabis crops.
The two biggest cannabis producers by ... | The two biggest cannabis producers by market cap, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC), also rank at the top when it comes to production capacity thanks to the construction of enormous indoor facilities. However, the shift to outdoor production is a smart move on the part of these companies for one... | The two biggest cannabis producers by market cap, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC), also rank at the top when it comes to production capacity thanks to the construction of enormous indoor facilities. Why it's a smart move Cannabis cultivated indoors or in greenhouses is usually viewed as having... | The two biggest cannabis producers by market cap, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC), also rank at the top when it comes to production capacity thanks to the construction of enormous indoor facilities. At the time of its announcement, Aurora stated that cannabis had already been planted at Aurora... | The two biggest cannabis producers by market cap, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC), also rank at the top when it comes to production capacity thanks to the construction of enormous indoor facilities. Now, though, both Aurora and Canopy are betting on outdoor production. Why it's a smart move Ca... |
38045.0 | 2019-10-10 00:00:00 UTC | FDA's Official Vape Warning Undermines Cannabis Industry's Growth Plans | ACB | https://www.nasdaq.com/articles/fdas-official-vape-warning-undermines-cannabis-industrys-growth-plans-2019-10-10 | nan | nan | Some marijuana investors may have quietly suspected the outbreak of hundreds of respiratory illnesses and at least 14 deaths among the "vaping" crowd was closely linked to the usage of tetrahydrocannabinol (THC), or the component of marijuana that creates a psychotropic euphoria. But it wasn't until Friday of last week... | That's a problem for some cannabis companies like Aurora Cannabis (NYSE: ACB) and KushCo (OTC: KSHB), both of which saw vaping as a key part of their growth plans. Aurora was the first licensed pot producer to launch a vape-ready CBD oil cartridge when Canada legalized marijuana a year ago, while the bulk of KushCo's b... | That's a problem for some cannabis companies like Aurora Cannabis (NYSE: ACB) and KushCo (OTC: KSHB), both of which saw vaping as a key part of their growth plans. Conversely, it's a paradigm shift that favors outfits like HEXO (NYSE: HEXO), which has been working on the development of cannabis edibles and beverages. C... | That's a problem for some cannabis companies like Aurora Cannabis (NYSE: ACB) and KushCo (OTC: KSHB), both of which saw vaping as a key part of their growth plans. In light of recent developments, the regulator bluntly wrote, "Do not use vaping products that contain THC" in a public statement, adding, "Do not modify or... | That's a problem for some cannabis companies like Aurora Cannabis (NYSE: ACB) and KushCo (OTC: KSHB), both of which saw vaping as a key part of their growth plans. FDA recommends not vaping THC There was no ambiguity about the FDA's stance. Canopy Growth (NYSE: CGC) CEO Mark Zekulin also clearly stated in September -- ... |
38046.0 | 2019-10-10 00:00:00 UTC | Better Buy: OrganiGram Holdings vs. Aurora Cannabis | ACB | https://www.nasdaq.com/articles/better-buy%3A-organigram-holdings-vs.-aurora-cannabis-2019-10-10 | nan | nan | Over the past 30 days, the broad-based sell-off in the legal marijuana space has accelerated in a big way. Numerous top dogs in the industry have seen their market caps shrink in drastic fashion during this period. However, the next wave of legalization in Canada (a.k.a. Cannabis 2.0) -- which will allow the sale of ca... | Canada's OrganiGram Holdings (NASDAQ: OGI) and Aurora Cannabis (NYSE: ACB) are two names in particular that could benefit tremendously from this industrywide tailwind. Thanks to its proprietary three-tier growing system, the company easily has one of the highest yields per square foot and one of the lowest costs of pro... | Canada's OrganiGram Holdings (NASDAQ: OGI) and Aurora Cannabis (NYSE: ACB) are two names in particular that could benefit tremendously from this industrywide tailwind. OrganiGram, in kind, stands to be one of the only Canadian pot companies to turn a profit on a consistent basis during the industry's early years. After... | Canada's OrganiGram Holdings (NASDAQ: OGI) and Aurora Cannabis (NYSE: ACB) are two names in particular that could benefit tremendously from this industrywide tailwind. OrganiGram, in kind, stands to be one of the only Canadian pot companies to turn a profit on a consistent basis during the industry's early years. * Dav... | Canada's OrganiGram Holdings (NASDAQ: OGI) and Aurora Cannabis (NYSE: ACB) are two names in particular that could benefit tremendously from this industrywide tailwind. Which of these top pot stocks is the better buy right now? 10 stocks we like better than Aurora Cannabis Inc. |
38047.0 | 2019-10-09 00:00:00 UTC | Aurora Cannabis Stock Is Down, But Not Dead | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock-is-down-but-not-dead-2019-10-09 | nan | nan | The days of cannabis stocks being all the rage are long gone. Now, spikes in stocks of companies like Aurora Cannabis (NYSE:) have been opportunities to sell. Regardless of the reason why, the appetite for pot stocks is but a fraction of what it used to be on Wall Street. Even the anointed kings of the sector like Cano... | But if the vast scope of applications for cannabis come to fruition, then the upside in the ACB stock price is tremendous. Once-beloved ACB stock is down 21% year-to-date. Source: Shutterstock Some of ACB’s pain is self-inflicted, thanks to bad headlines. | Use Proper Levels to Trade ACB Stock If ACB stock bulls can break and close above $4.60 per share, then they could have a base on which they can mount a recovery rally. Once-beloved ACB stock is down 21% year-to-date. Source: Shutterstock Some of ACB’s pain is self-inflicted, thanks to bad headlines. | Aurora Stock Is Not Doomed Yet So far the long-term thesis is simple: Buy ACB stock and hold it for years to come. Alternatively, ACB stock has clear short-term levels that active traders can use to profit in the meantime. Use Proper Levels to Trade ACB Stock If ACB stock bulls can break and close above $4.60 per share... | Use Proper Levels to Trade ACB Stock If ACB stock bulls can break and close above $4.60 per share, then they could have a base on which they can mount a recovery rally. Once-beloved ACB stock is down 21% year-to-date. Source: Shutterstock Some of ACB’s pain is self-inflicted, thanks to bad headlines. |
38048.0 | 2019-10-09 00:00:00 UTC | Will October See a Third Country Legalize Marijuana? | ACB | https://www.nasdaq.com/articles/will-october-see-a-third-country-legalize-marijuana-2019-10-09 | nan | nan | Canada and Uruguay are still the only two countries that have legalized marijuana for recreational use thus far. Much of the progress that has been made on cannabis legislation has largely been related to medical use. However, there could soon be a third country to legalize recreational marijuana: Mexico.
Although the ... | Huge opportunity that could come with significant risks Aurora Cannabis (NYSE: ACB) has been eyeing the Mexican market and could be in a great position to benefit from legalization there. Too many options could lead to little progress being made One of the big issues Mexico is grappling with is whether or not a governm... | Huge opportunity that could come with significant risks Aurora Cannabis (NYSE: ACB) has been eyeing the Mexican market and could be in a great position to benefit from legalization there. However, there could soon be a third country to legalize recreational marijuana: Mexico. After all, the newsletter they have run for... | Huge opportunity that could come with significant risks Aurora Cannabis (NYSE: ACB) has been eyeing the Mexican market and could be in a great position to benefit from legalization there. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Aurora Cannabis Inc. was... | Huge opportunity that could come with significant risks Aurora Cannabis (NYSE: ACB) has been eyeing the Mexican market and could be in a great position to benefit from legalization there. And given the court's view that it should be the right of citizens to be able to consume cannabis for personal use, it would appear ... |
38049.0 | 2019-10-09 00:00:00 UTC | Tale of 3 Cannabis Stocks: Two with Cash Infusions, One Without | ACB | https://www.nasdaq.com/articles/tale-of-3-cannabis-stocks%3A-two-with-cash-infusions-one-without-2019-10-09 | nan | nan | Aurora Cannabis, Canopy Growth and Cronos Group have driven much of the attention in the cannabis sector for some time, as Canopy and Cronos were known for receiving huge cash infusions from Constellation Brands and Altria, while Aurora was noted for resisting the same, looking to carve its own destiny without giving u... | Aurora Cannabis (ACB) Going It Alone When taking into consideration the huge investments Canopy and Cronos received, and it having little impact on the performances of the companies, it reinforces to me that Aurora made the right decision in going it alone. The fact that Jody Begley, senior vice president of tobacco pr... | Aurora Cannabis (ACB) Going It Alone When taking into consideration the huge investments Canopy and Cronos received, and it having little impact on the performances of the companies, it reinforces to me that Aurora made the right decision in going it alone. Aurora Cannabis, Canopy Growth and Cronos Group have driven mu... | Aurora Cannabis (ACB) Going It Alone When taking into consideration the huge investments Canopy and Cronos received, and it having little impact on the performances of the companies, it reinforces to me that Aurora made the right decision in going it alone. Aurora Cannabis, Canopy Growth and Cronos Group have driven mu... | Aurora Cannabis (ACB) Going It Alone When taking into consideration the huge investments Canopy and Cronos received, and it having little impact on the performances of the companies, it reinforces to me that Aurora made the right decision in going it alone. Aurora Cannabis, Canopy Growth and Cronos Group have driven mu... |
38050.0 | 2019-10-09 00:00:00 UTC | Don’t Give Up on These 4 Cannabis Stocks | ACB | https://www.nasdaq.com/articles/dont-give-up-on-these-4-cannabis-stocks-2019-10-09 | nan | nan | Once high-flying cannabis stocks have come crashing down over the past few months. After starting off 2019 on good footing, investors grew optimistic with respect to the growing Canadian market, U.S. federal legalization and new edible cannabis products. Then cannabis stocks started crashing down as all of the industry... | Aurora (ACB) Source: Jarretera / Shutterstock.com Percent Off All-Time Highs: 65% In terms of kilograms of cannabis sold last quarter, Aurora (NYSE:) is the biggest player in the Canadian cannabis market. ACB stock isn’t priced for any of this. As of this writing, Luke Lango was long CGC, APHA and ACB. | Aurora (ACB) Source: Jarretera / Shutterstock.com Percent Off All-Time Highs: 65% In terms of kilograms of cannabis sold last quarter, Aurora (NYSE:) is the biggest player in the Canadian cannabis market. ACB stock isn’t priced for any of this. As of this writing, Luke Lango was long CGC, APHA and ACB. | Aurora (ACB) Source: Jarretera / Shutterstock.com Percent Off All-Time Highs: 65% In terms of kilograms of cannabis sold last quarter, Aurora (NYSE:) is the biggest player in the Canadian cannabis market. ACB stock isn’t priced for any of this. As of this writing, Luke Lango was long CGC, APHA and ACB. | Aurora (ACB) Source: Jarretera / Shutterstock.com Percent Off All-Time Highs: 65% In terms of kilograms of cannabis sold last quarter, Aurora (NYSE:) is the biggest player in the Canadian cannabis market. ACB stock isn’t priced for any of this. As of this writing, Luke Lango was long CGC, APHA and ACB. |
38051.0 | 2019-10-09 00:00:00 UTC | Aurora Cannabis Rolls Out Cannabis Strips | ACB | https://www.nasdaq.com/articles/aurora-cannabis-rolls-out-cannabis-strips-2019-10-09 | nan | nan | These days, when it comes to cannabis, you can smoke it, eat it, and drink it. But now there's a new way to consume cannabis: strips that dissolve in the mouth.
This is thanks to top Canadian marijuana stock Aurora Cannabis (NYSE: ACB), which announced Tuesday that it has launched cannabinoid-infused "sublingual wafers... | This is thanks to top Canadian marijuana stock Aurora Cannabis (NYSE: ACB), which announced Tuesday that it has launched cannabinoid-infused "sublingual wafers" -- i.e., thin strips meant to be held under the tongue until they dissolve to nothing. It also did not mention any possibility of rolling out or modifying the ... | This is thanks to top Canadian marijuana stock Aurora Cannabis (NYSE: ACB), which announced Tuesday that it has launched cannabinoid-infused "sublingual wafers" -- i.e., thin strips meant to be held under the tongue until they dissolve to nothing. The company titles this particular form factor Orally Dissolvable Thin F... | This is thanks to top Canadian marijuana stock Aurora Cannabis (NYSE: ACB), which announced Tuesday that it has launched cannabinoid-infused "sublingual wafers" -- i.e., thin strips meant to be held under the tongue until they dissolve to nothing. Dissolve Strips were developed by Aurora in conjunction with fellow Cana... | This is thanks to top Canadian marijuana stock Aurora Cannabis (NYSE: ACB), which announced Tuesday that it has launched cannabinoid-infused "sublingual wafers" -- i.e., thin strips meant to be held under the tongue until they dissolve to nothing. But now there's a new way to consume cannabis: strips that dissolve in t... |
38052.0 | 2019-10-08 00:00:00 UTC | 2 Ways Aurora Cannabis Could Pay the Price for Its Aggressive Growth Strategy | ACB | https://www.nasdaq.com/articles/2-ways-aurora-cannabis-could-pay-the-price-for-its-aggressive-growth-strategy-2019-10-08 | nan | nan | Aurora Cannabis (TSX: ACB) is one of the most popular marijuana companies, particularly among millennials. The pot grower famously ranked as the top stock holding on Robinhood. Aurora isn't just popular among younger demographics, though, with several analysts giving the company a nod of approval in the form of a buy r... | Aurora Cannabis (TSX: ACB) is one of the most popular marijuana companies, particularly among millennials. Aurora isn't just popular among younger demographics, though, with several analysts giving the company a nod of approval in the form of a buy rating earlier this year. However, due to its status as a start-up -- n... | Aurora Cannabis (TSX: ACB) is one of the most popular marijuana companies, particularly among millennials. By implementing an aggressive growth strategy marked by acquisitions, international expansion, and strong efforts to ramp up its production capacity. In accounting terms, it represents the difference between the a... | Aurora Cannabis (TSX: ACB) is one of the most popular marijuana companies, particularly among millennials. However, due to its status as a start-up -- not to mention other barriers caused by the nature of its business activities -- Aurora didn't always have the means to fund these efforts, and the company turned to dil... | Aurora Cannabis (TSX: ACB) is one of the most popular marijuana companies, particularly among millennials. Aurora has already issued about 1 billion shares in its race to the top of the marijuana industry. In other words, Aurora isn't done having to deal with its share dilution problems. |
38053.0 | 2019-10-08 00:00:00 UTC | 3 Interesting Catalysts Will Boost Aurora Cannabis Stock | ACB | https://www.nasdaq.com/articles/3-interesting-catalysts-will-boost-aurora-cannabis-stock-2019-10-08 | nan | nan | Aurora Cannabis (NYSE:) reported its fiscal fourth-quarter earnings a month ago. Thanks to Aurora’s poor results and guidance, ACB stock has lost 32% of its value since then.
Source: Shutterstock
Now trading at less than $4.50 per share, ACB stock should soon bounce back as a result of these three catalysts.
Aurora Pol... | And the fact that ACB is keeping up with the latest indoor growing technology means even those who live in smaller spaces can produce lower-cost cannabis. It might not be a huge revenue generator for the company, but it does provide ACB’s consumers with an alternative until more retail cannabis shops open across the co... | In British Columbia, ACB has 55,000 cannabis plants. Thanks to Aurora’s poor results and guidance, ACB stock has lost 32% of its value since then. Source: Shutterstock Now trading at less than $4.50 per share, ACB stock should soon bounce back as a result of these three catalysts. | Aurora Polaris Is Nearly Complete The news that construction of Aurora Polaris — ACB’s production facility for higher-margin, value-added products such as edibles — ought to please the owners of Aurora Cannabis stock. Thanks to Aurora’s poor results and guidance, ACB stock has lost 32% of its value since then. Source... | Aurora Polaris Is Nearly Complete The news that construction of Aurora Polaris — ACB’s production facility for higher-margin, value-added products such as edibles — ought to please the owners of Aurora Cannabis stock. Thanks to Aurora’s poor results and guidance, ACB stock has lost 32% of its value since then. Source... |
38054.0 | 2019-10-08 00:00:00 UTC | Hold Your Nose and Buy Canopy Growth Stock | ACB | https://www.nasdaq.com/articles/hold-your-nose-and-buy-canopy-growth-stock-2019-10-08 | nan | nan | Canopy Growth (NYSE:) stock is down almost 10% since Bank of America downgraded the stock on Sept. 27. CGC stock is now down more than 54% overall in the past year. But investors need to understand more than just the downgrade headline.
Source: Shutterstock
I can’t say with any certainty that things are going to get be... | In my opinion, the best way to play CGC stock and minimize risk is to include it in a basket of other top cannabis plays, including ACB stock, GW Pharmaceuticals (NASDAQ:) and others. “To be clear, we still see Canopy as a long-term leader in an industry with a large and growing Total Addressable Market (TAM), increasi... | In my opinion, the best way to play CGC stock and minimize risk is to include it in a basket of other top cannabis plays, including ACB stock, GW Pharmaceuticals (NASDAQ:) and others. In fact, even in his downgrade note, Bank of America analyst Christopher Carey said Canopy is still a cannabis market leader. “We contin... | In my opinion, the best way to play CGC stock and minimize risk is to include it in a basket of other top cannabis plays, including ACB stock, GW Pharmaceuticals (NASDAQ:) and others. Canopy Growth (NYSE:) stock is down almost 10% since Bank of America downgraded the stock on Sept. 27. How to Play CGC Stock CGC stock i... | In my opinion, the best way to play CGC stock and minimize risk is to include it in a basket of other top cannabis plays, including ACB stock, GW Pharmaceuticals (NASDAQ:) and others. In fact, even in his downgrade note, Bank of America analyst Christopher Carey said Canopy is still a cannabis market leader. In additio... |
38055.0 | 2019-10-08 00:00:00 UTC | Aurora Cannabis (ACB) Stock Remains a Solid Long-Term Holding | ACB | https://www.nasdaq.com/articles/aurora-cannabis-acb-stock-remains-a-solid-long-term-holding-2019-10-08 | nan | nan | When there's blood in the streets, all the naysayers come out and focus primarily on things that theoretically could go wrong with a company, and theoretically, what could happen in a specific market. That is happening with Aurora Cannabis (ACB) and other cannabis companies at this time, and also with the cannabis mark... | That is happening with Aurora Cannabis (ACB) and other cannabis companies at this time, and also with the cannabis market generally. Jefferies analyst Owen Bennett just recently reiterated a Buy rating on ACB with a C$14.00 price target, suggesting the stock could rise over 150% in the next 12 months. (See ACB stock an... | That is happening with Aurora Cannabis (ACB) and other cannabis companies at this time, and also with the cannabis market generally. Jefferies analyst Owen Bennett just recently reiterated a Buy rating on ACB with a C$14.00 price target, suggesting the stock could rise over 150% in the next 12 months. (See ACB stock an... | That is happening with Aurora Cannabis (ACB) and other cannabis companies at this time, and also with the cannabis market generally. Jefferies analyst Owen Bennett just recently reiterated a Buy rating on ACB with a C$14.00 price target, suggesting the stock could rise over 150% in the next 12 months. (See ACB stock an... | That is happening with Aurora Cannabis (ACB) and other cannabis companies at this time, and also with the cannabis market generally. Jefferies analyst Owen Bennett just recently reiterated a Buy rating on ACB with a C$14.00 price target, suggesting the stock could rise over 150% in the next 12 months. (See ACB stock an... |
38056.0 | 2019-10-08 00:00:00 UTC | 3 Marijuana Stocks With Top-Notch Transparency | ACB | https://www.nasdaq.com/articles/3-marijuana-stocks-with-top-notch-transparency-2019-10-08 | nan | nan | Over the next decade, you'd probably struggle to find a growth opportunity that's more exciting than legal cannabis. With Canada giving recreational marijuana the green light last October, Mexico expected to follow suit very soon, and more U.S. states legalizing pot, the door is wide open for marijuana stocks to thrive... | Aurora Cannabis Among pure-play marijuana growers, perhaps no company is more upfront with its shareholders than Aurora Cannabis (NYSE: ACB). Although the company wound up whiffing on its own sales guidance in its most recent quarter, the simple fact that investors and Wall Street have a pretty good idea of what to exp... | Aurora Cannabis Among pure-play marijuana growers, perhaps no company is more upfront with its shareholders than Aurora Cannabis (NYSE: ACB). Innovative Industrial Properties Cannabis real estate investment trust (REIT) Innovative Industrial Properties (NYSE: IIPR) also deserves a nod for keeping its shareholders up to... | Aurora Cannabis Among pure-play marijuana growers, perhaps no company is more upfront with its shareholders than Aurora Cannabis (NYSE: ACB). Innovative Industrial Properties Cannabis real estate investment trust (REIT) Innovative Industrial Properties (NYSE: IIPR) also deserves a nod for keeping its shareholders up to... | Aurora Cannabis Among pure-play marijuana growers, perhaps no company is more upfront with its shareholders than Aurora Cannabis (NYSE: ACB). Image source: Planet 13. The Motley Fool recommends CannTrust Holdings Inc, Innovative Industrial Properties, and Namaste Technologies. |
38057.0 | 2019-10-08 00:00:00 UTC | How Big a Deal Is Canopy Growth's Recent Sports Beverage Acquisition? | ACB | https://www.nasdaq.com/articles/how-big-a-deal-is-canopy-growths-recent-sports-beverage-acquisition-2019-10-08 | nan | nan | Investors found themselves a little surprised on Friday after the industry's largest cannabis company announced a peculiar acquisition. Canopy Growth (NYSE: CGC) bought a majority stake in BioSteel Sports Nutrition, a major sports-beverage company that has partnered with numerous sports teams across North America. This... | Although other cannabis giants such as Aurora Cannabis (NYSE: ACB) have made their own forays into the athletics market, Canopy's buyout of BioSteel puts it ahead of its competitors in this high-growth niche. However, he has recently been leaning to the cannabis space instead due to many athletes complaining of chronic... | Although other cannabis giants such as Aurora Cannabis (NYSE: ACB) have made their own forays into the athletics market, Canopy's buyout of BioSteel puts it ahead of its competitors in this high-growth niche. Canopy Growth (NYSE: CGC) bought a majority stake in BioSteel Sports Nutrition, a major sports-beverage company... | Although other cannabis giants such as Aurora Cannabis (NYSE: ACB) have made their own forays into the athletics market, Canopy's buyout of BioSteel puts it ahead of its competitors in this high-growth niche. Canopy Growth (NYSE: CGC) bought a majority stake in BioSteel Sports Nutrition, a major sports-beverage company... | Although other cannabis giants such as Aurora Cannabis (NYSE: ACB) have made their own forays into the athletics market, Canopy's buyout of BioSteel puts it ahead of its competitors in this high-growth niche. While some investors had hoped that Canopy would slow down on acquisitions following these losses, some signifi... |
38058.0 | 2019-10-08 00:00:00 UTC | Hexo Stock Could Rally, But It’s Quite Risky | ACB | https://www.nasdaq.com/articles/hexo-stock-could-rally-but-its-quite-risky-2019-10-08 | nan | nan | HEXO (NYSE:) stock remains in an uncertain position in the Canadian marijuana market. It has not achieved the top-tier status of Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), Cronos Group (NASDAQ:), or Tilray (NASDAQ:).
Source: Shutterstock
However, HEXO also retains significant market share in the key Canadian provi... | Source: Shutterstock However, HEXO also retains significant market share in the key Canadian province of Quebec. Assuming Truss succeeds, it could lead to other deals for HEXO that will increase its market share in Canada and help it to expand overseas. However, with Hexo stock price now below $4 per share, the questio... | HEXO (NYSE:) stock remains in an uncertain position in the Canadian marijuana market. The Bottom Line on Hexo Stock For investors open to higher risks, Hexo stock holds a great deal of potential. Despite the company’s lack of market leadership, its significant market share in Quebec and its partnership with Molson Coor... | For those who can stomach the risk and uncertainty of Hexo stock, these benefits could eventually turn HEXO into one of the more lucrative marijuana stocks.— One example of the company’s lack of stability came on Friday. The Bottom Line on Hexo Stock For investors open to higher risks, Hexo stock holds a great deal of ... | HEXO (NYSE:) stock remains in an uncertain position in the Canadian marijuana market. The Bottom Line on Hexo Stock For investors open to higher risks, Hexo stock holds a great deal of potential. Despite the company’s lack of market leadership, its significant market share in Quebec and its partnership with Molson Coor... |
38059.0 | 2019-10-07 00:00:00 UTC | Will Federal Legalization Occur in Time to Save Aurora Cannabis Stock? | ACB | https://www.nasdaq.com/articles/will-federal-legalization-occur-in-time-to-save-aurora-cannabis-stock-2019-10-07-0 | nan | nan | There are two questions investors should ask regarding Aurora Cannabis (NYSE:), and indeed, any cannabis stock. How long must investors wait before marijuana is treated like tobacco? And does your target company have enough cash to get there?
Source: Shutterstock
These are the questions I started to ask last month, whe... | ACB is selling a drug it hopes will be made legal, just as tobacco companies sell a drug they hope won’t be made illegal. The Bottom Line on ACB Stock Marijuana is a drug, not a cure. Source: Shutterstock These are the questions I started to ask last month, when I wrote about New technologies always go through a hype c... | ACB is selling a drug it hopes will be made legal, just as tobacco companies sell a drug they hope won’t be made illegal. The Bottom Line on ACB Stock Marijuana is a drug, not a cure. There are two questions investors should ask regarding Aurora Cannabis (NYSE:), and indeed, any cannabis stock. | ACB is selling a drug it hopes will be made legal, just as tobacco companies sell a drug they hope won’t be made illegal. The Bottom Line on ACB Stock Marijuana is a drug, not a cure. Waiting for Godot The bull case on Aurora, as described by InvestorPlace’s , is that the company will be able to quickly ramp up product... | ACB is selling a drug it hopes will be made legal, just as tobacco companies sell a drug they hope won’t be made illegal. The Bottom Line on ACB Stock Marijuana is a drug, not a cure. There are two questions investors should ask regarding Aurora Cannabis (NYSE:), and indeed, any cannabis stock. |
38060.0 | 2019-10-07 00:00:00 UTC | 3 Pot Stocks Poised to Benefit From the CBD Sports Market | ACB | https://www.nasdaq.com/articles/3-pot-stocks-poised-to-benefit-from-the-cbd-sports-market-2019-10-07 | nan | nan | The legalization of hemp via the 2018 Farm Bill opened up exciting new markets for cannabis companies. While marijuana remains an illegal at the federal level as a Schedule 1 Controlled Substance, cannabidiol extracts, or CBD, is completely legal in the U.S. with certain FDA restrictions. CBD is popular in health and w... | (See Canopy stock analysis on TipRanks) Aurora Cannabis (ACB) Similar to Canopy Growth, Aurora Cannabis lacks a business in the U.S. Out of 11 analysts polled in the last 3 months, 3 bulls are betting on ACB stock, 6 are hedging their bet, and 2 bears are saying now is the time to sell. The American Journal on Addictio... | (See Canopy stock analysis on TipRanks) Aurora Cannabis (ACB) Similar to Canopy Growth, Aurora Cannabis lacks a business in the U.S. Out of 11 analysts polled in the last 3 months, 3 bulls are betting on ACB stock, 6 are hedging their bet, and 2 bears are saying now is the time to sell. We’ve delved into three companie... | (See Canopy stock analysis on TipRanks) Aurora Cannabis (ACB) Similar to Canopy Growth, Aurora Cannabis lacks a business in the U.S. Out of 11 analysts polled in the last 3 months, 3 bulls are betting on ACB stock, 6 are hedging their bet, and 2 bears are saying now is the time to sell. We’ve delved into three companie... | (See Canopy stock analysis on TipRanks) Aurora Cannabis (ACB) Similar to Canopy Growth, Aurora Cannabis lacks a business in the U.S. Out of 11 analysts polled in the last 3 months, 3 bulls are betting on ACB stock, 6 are hedging their bet, and 2 bears are saying now is the time to sell. Any company that can build brand... |
38061.0 | 2019-10-07 00:00:00 UTC | ACB Stock May Be Unpredictable Now, but It’s Certain to Find Its Feet | ACB | https://www.nasdaq.com/articles/acb-stock-may-be-unpredictable-now-but-its-certain-to-find-its-feet-2019-10-07 | nan | nan | I’m bullish on the long-term future for Aurora Cannabis (NYSE:). It’s a case I made about a month ago. This was right after ACB stock continued to fall after its fourth-quarter earnings report.
Source: ElRoi / Shutterstock.com
I believe that due to unrealistic expectations. The asset bubble of cannabis has popped, and ... | In its fourth-quarter earnings report conference call in September, Aurora CEO Terry Booth had suggested that the company had been on a multistate operator review tour and casually mentioned that “probably 90% of my time is dealt on new opportunities.” Cash Burn and ACB Stock The reason this is important is that ACB is... | In its fourth-quarter earnings report conference call in September, Aurora CEO Terry Booth had suggested that the company had been on a multistate operator review tour and casually mentioned that “probably 90% of my time is dealt on new opportunities.” Cash Burn and ACB Stock The reason this is important is that ACB is... | In its fourth-quarter earnings report conference call in September, Aurora CEO Terry Booth had suggested that the company had been on a multistate operator review tour and casually mentioned that “probably 90% of my time is dealt on new opportunities.” Cash Burn and ACB Stock The reason this is important is that ACB is... | In its fourth-quarter earnings report conference call in September, Aurora CEO Terry Booth had suggested that the company had been on a multistate operator review tour and casually mentioned that “probably 90% of my time is dealt on new opportunities.” Cash Burn and ACB Stock The reason this is important is that ACB is... |
38062.0 | 2019-10-07 00:00:00 UTC | Will Federal Legalization Occur in Time to Save Aurora Cannabis Stock? | ACB | https://www.nasdaq.com/articles/will-federal-legalization-occur-in-time-to-save-aurora-cannabis-stock-2019-10-07 | nan | nan | There are two questions investors should ask regarding Aurora Cannabis (NYSE:), and indeed, any cannabis stock. How long must investors wait before marijuana is treated like tobacco? And does your target company have enough cash to get there?
Source: Shutterstock
These are the questions I started to ask last month, whe... | ACB is selling a drug it hopes will be made legal, just as tobacco companies sell a drug they hope won’t be made illegal. The Bottom Line on ACB Stock Marijuana is a drug, not a cure. Source: Shutterstock These are the questions I started to ask last month, when I wrote about New technologies always go through a hype c... | ACB is selling a drug it hopes will be made legal, just as tobacco companies sell a drug they hope won’t be made illegal. The Bottom Line on ACB Stock Marijuana is a drug, not a cure. There are two questions investors should ask regarding Aurora Cannabis (NYSE:), and indeed, any cannabis stock. | ACB is selling a drug it hopes will be made legal, just as tobacco companies sell a drug they hope won’t be made illegal. The Bottom Line on ACB Stock Marijuana is a drug, not a cure. Waiting for Godot The bull case on Aurora, as described by InvestorPlace’s , is that the company will be able to quickly ramp up product... | ACB is selling a drug it hopes will be made legal, just as tobacco companies sell a drug they hope won’t be made illegal. The Bottom Line on ACB Stock Marijuana is a drug, not a cure. There are two questions investors should ask regarding Aurora Cannabis (NYSE:), and indeed, any cannabis stock. |
38063.0 | 2019-10-07 00:00:00 UTC | Marijuana's "Big Four" Lost Nearly $14 Billion in Value During the Third Quarter | ACB | https://www.nasdaq.com/articles/marijuanas-big-four-lost-nearly-%2414-billion-in-value-during-the-third-quarter-2019-10-07 | nan | nan | For years, the marijuana industry has been an unstoppable force. Many of marijuana's biggest and best-known names have delivered substantial gains for investors, driven by aggressive growth projections for the pot industry.
After logging $10.9 billion in global sales last year, the duo of Arcview Market Research and BD... | Marijuana's "Big Four" -- Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) -- collectively shed close to $14 billion in market value during the third quarter. Many of marijuana's biggest and best-known names have delivered substantial gains for investors, dr... | Marijuana's "Big Four" -- Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) -- collectively shed close to $14 billion in market value during the third quarter. The biggest red mark being the roughly CA$2 billion in goodwill derived from its CA$2.64 billion de... | Marijuana's "Big Four" -- Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) -- collectively shed close to $14 billion in market value during the third quarter. On top of Aurora's mammoth goodwill, Canopy Growth has CA$1.93 billion in goodwill following a slew... | Marijuana's "Big Four" -- Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) -- collectively shed close to $14 billion in market value during the third quarter. Aurora Cannabis: $3.49 billion. In fact, Aurora mentioned this in its fiscal fourth-quarter operati... |
38064.0 | 2019-10-06 00:00:00 UTC | Better Buy: Aurora Cannabis vs. Canopy Growth | ACB | https://www.nasdaq.com/articles/better-buy%3A-aurora-cannabis-vs.-canopy-growth-2019-10-06 | nan | nan | Marijuana stocks have hit a rough patch in the back half of 2019. But there are still plenty of reasons to like this group of equities, especially as long-term buy-and-hold plays. After all, legal cannabis is widely expected to be the fastest growing industry in the world over the next decade.
Keeping with this theme,... | Keeping with this theme, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) are locked in a heated battle to become the industry's alpha dog. Aurora's massive scale, in turn, has already produced top-shelf gross margin (58% in the last quarter), lower cost of production for dried flowers, and outsize shares of b... | Keeping with this theme, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) are locked in a heated battle to become the industry's alpha dog. Unlike Canopy Growth and Cronos Group, Aurora hasn't onboarded a major equity partner yet. The case for Canopy Canopy has three main selling points to potential investors:... | Keeping with this theme, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) are locked in a heated battle to become the industry's alpha dog. The case for Aurora Aurora has been a fan favorite among retail investors ever since its debut on the New York Stock Exchange last year. The case for Canopy Canopy has thr... | Keeping with this theme, Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) are locked in a heated battle to become the industry's alpha dog. Aurora's massive scale, in turn, has already produced top-shelf gross margin (58% in the last quarter), lower cost of production for dried flowers, and outsize shares of b... |
38065.0 | 2019-10-06 00:00:00 UTC | 2 Best Cannabis Stocks to Buy in October | ACB | https://www.nasdaq.com/articles/2-best-cannabis-stocks-to-buy-in-october-2019-10-06 | nan | nan | The cannabis stock bubble has burst. There's no denying it in light of the industry's dreadful performance over the prior six months. Industry heavyweights Aurora Cannabis and Cronos Group, after all, have lost over half their value since the end of the first-quarter. Moreover, Canopy Growth also saw its shares dip by ... | Moreover, Canopy Growth also saw its shares dip by a whopping 47% during this period, despite its top dog status within the adult-use recreational marijuana space in Canada and its partnership with alcoholic beverage titan Constellation Brands. Canada's third largest pot cultivator, Aphria (NYSE: APHA), and U.S.-based ... | Industry heavyweights Aurora Cannabis and Cronos Group, after all, have lost over half their value since the end of the first-quarter. That's a markedly cheaper valuation than Aurora, Canopy Growth, or Cronos Group. The Motley Fool recommends Charlotte's Web, Constellation Brands, and CVS Health. | Canada's third largest pot cultivator, Aphria (NYSE: APHA), and U.S.-based pure hemp play Charlotte's Web Holdings (OTC: CWBHF) could both prove to be stellar growth vehicles over the next 12 months. Despite these positive business developments and the enormous demand for CBD products, though, Charlotte's Web's shares ... | Aphria is simply too cheap There are three solid reasons to consider adding Aphria to your portfolio this month. Second, Aphria is one of the few Canadian pot cultivators that's profitable. The Motley Fool recommends Charlotte's Web, Constellation Brands, and CVS Health. |
38066.0 | 2019-10-06 00:00:00 UTC | How Risky Is Aurora Cannabis' Big Bet on Cannabis 2.0? | ACB | https://www.nasdaq.com/articles/how-risky-is-aurora-cannabis-big-bet-on-cannabis-2.0-2019-10-06 | nan | nan | Every major Canadian cannabis producer is gearing up for what has been dubbed "Cannabis 2.0." The next stage in the process by which that country is legalizing adult-use recreational marijuana will bring several new types of cannabis-derived products to the market.
Aurora Cannabis (NYSE: ACB) is as excited about those ... | Aurora Cannabis (NYSE: ACB) is as excited about those new opportunities as any of its rivals. The company has invested heavily in anticipation of the market for them officially opening this month, although sales of those products won't begin until after a required 60-day notification window that ends in mid-December. B... | Aurora Cannabis (NYSE: ACB) is as excited about those new opportunities as any of its rivals. Every major Canadian cannabis producer is gearing up for what has been dubbed "Cannabis 2.0." But Aurora is making a big bet on one type of product for the Cannabis 2.0 market. | Aurora Cannabis (NYSE: ACB) is as excited about those new opportunities as any of its rivals. In the company's fiscal 2019 third-quarter conference call in May, Aurora Chief Corporate Officer Cam Battley stated that he thinks that vapes will be "a terrific market segment that doesn't need a lot of market development." ... | Aurora Cannabis (NYSE: ACB) is as excited about those new opportunities as any of its rivals. But Aurora is making a big bet on one type of product for the Cannabis 2.0 market. Aurora doesn't. |
38067.0 | 2019-10-05 00:00:00 UTC | Marijuana Value Traps Do Exist: Here Are 3 to Avoid | ACB | https://www.nasdaq.com/articles/marijuana-value-traps-do-exist%3A-here-are-3-to-avoid-2019-10-05 | nan | nan | Investors would have a hard time finding an industry with more impressive long-term growth potential than legal cannabis. After generating close to $11 billion in worldwide sales last year, some on Wall Street foresee anywhere from $50 billion on the low end to as much as $200 billion on the high end in global sales by... | Aurora Cannabis Among millennial investors, there isn't a more popular company on the planet than Aurora Cannabis (NYSE: ACB). The Horizons Marijuana Life Sciences ETF, the first exchange-traded fund focused on cannabis, has lost nearly half of its value over that time, which in investors' eyes may be creating some int... | Aurora Cannabis Among millennial investors, there isn't a more popular company on the planet than Aurora Cannabis (NYSE: ACB). iAnthus Capital Holdings In terms of price-to-book ratio, no marijuana stock is cheaper than iAnthus Capital Holdings (OTC: ITHUF). At the end of the company's June quarter, iAnthus had CA$440.... | Aurora Cannabis Among millennial investors, there isn't a more popular company on the planet than Aurora Cannabis (NYSE: ACB). This makes it far more likely that the company will have to redeem these notes with cash, rather than stock, and also increases the likelihood of Aurora issuing more stock to raise capital. At ... | Aurora Cannabis Among millennial investors, there isn't a more popular company on the planet than Aurora Cannabis (NYSE: ACB). This makes it far more likely that the company will have to redeem these notes with cash, rather than stock, and also increases the likelihood of Aurora issuing more stock to raise capital. iAn... |
38068.0 | 2019-10-04 00:00:00 UTC | Why Aurora Cannabis Fell 20.7% in September | ACB | https://www.nasdaq.com/articles/why-aurora-cannabis-fell-20.7-in-september-2019-10-04 | nan | nan | What happened
Aurora Cannabis (NYSE: ACB) saw its stock fall 20.7% in the month of September, according to data from S&P Global Market Intelligence. The world's leading producer of cannabis sold off after a tough month for pot stocks and unprofitable growth stocks in general. In addition, Aurora released a fiscal fourt... | What happened Aurora Cannabis (NYSE: ACB) saw its stock fall 20.7% in the month of September, according to data from S&P Global Market Intelligence. Nevertheless, missing your targets, especially in a new and evolving industry such as cannabis, isn't going to do any favors for your credibility with Wall Street, and Aur... | What happened Aurora Cannabis (NYSE: ACB) saw its stock fall 20.7% in the month of September, according to data from S&P Global Market Intelligence. So what In its fiscal fourth quarter, Aurora reported revenue of $99 million and an adjusted EBITDA loss of $11.7 million. Aurora Cannabis missed revenue expectations. | What happened Aurora Cannabis (NYSE: ACB) saw its stock fall 20.7% in the month of September, according to data from S&P Global Market Intelligence. Aurora management gave a pretty decent explanation of the shortfall -- the company actually met the high end of its cannabis sales guidance of $95 million, but the company... | What happened Aurora Cannabis (NYSE: ACB) saw its stock fall 20.7% in the month of September, according to data from S&P Global Market Intelligence. Aurora Cannabis missed revenue expectations. Now what All Canadian cannabis companies are dealing with some oversupply in the market due to a delay in approvals for Canadi... |
38069.0 | 2019-10-04 00:00:00 UTC | Should Investors Have More Patience with Tilray Stock? | ACB | https://www.nasdaq.com/articles/should-investors-have-more-patience-with-tilray-stock-2019-10-04 | nan | nan | Tilray (NASDAQ:TLRY) stock has been in a downtrend since it rose to $214.06 after being the first cannabis company to go public. The stock is now trading below $25 per share ($24.88 as of this writing) and has a market capitalization of $2.36 billion. And as InvestorPlace contributor Will Ashworth wrote in an earlier a... | Many of the leading cannabis stocks such as Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) are making major investments to increase their growing and production facilities. Tilray Isn’t Playing the Production Game The cannabis industry is still sorting out the market dynamics of supply and demand. One of the r... | Many of the leading cannabis stocks such as Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) are making major investments to increase their growing and production facilities. Tilray (NASDAQ:TLRY) stock has been in a downtrend since it rose to $214.06 after being the first cannabis company to go public. However, ... | Many of the leading cannabis stocks such as Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) are making major investments to increase their growing and production facilities. Tilray (NASDAQ:TLRY) stock has been in a downtrend since it rose to $214.06 after being the first cannabis company to go public. Tilray Is... | Many of the leading cannabis stocks such as Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) are making major investments to increase their growing and production facilities. One of the reasons Tilray stock was punished this year is that the company was viewed as being more susceptible to supply problems. In fac... |
38070.0 | 2019-10-04 00:00:00 UTC | The Elephant in the Room With Aurora Cannabis' Latest Update | ACB | https://www.nasdaq.com/articles/the-elephant-in-the-room-with-aurora-cannabis-latest-update-2019-10-04 | nan | nan | Aurora Cannabis (NYSE: ACB) doesn't make investors wait until the company's financial reports each quarter to shed light on what's going on with its operations. The Canadian cannabis producer has committed to "provide regular, quarterly updates to its stakeholders in an effort to demonstrate continued transparency and ... | Aurora Cannabis (NYSE: ACB) doesn't make investors wait until the company's financial reports each quarter to shed light on what's going on with its operations. Aurora mentioned some efforts, including its recent agreements with two partners in the United Kingdom aimed at speeding up the delivery of more medical cannab... | Aurora Cannabis (NYSE: ACB) doesn't make investors wait until the company's financial reports each quarter to shed light on what's going on with its operations. Aurora CEO Terry Booth stated that the company's 1.6 million square-foot Aurora Sun facility in Alberta "is nearing completion with the majority of capital inv... | Aurora Cannabis (NYSE: ACB) doesn't make investors wait until the company's financial reports each quarter to shed light on what's going on with its operations. Aurora CEO Terry Booth stated that the company's 1.6 million square-foot Aurora Sun facility in Alberta "is nearing completion with the majority of capital inv... | Aurora Cannabis (NYSE: ACB) doesn't make investors wait until the company's financial reports each quarter to shed light on what's going on with its operations. Not all of Aurora's business update was about construction efforts. Investing in marijuana stocks often doesn't come with enough transparency. |
38071.0 | 2019-10-03 00:00:00 UTC | Why Okta, Cleveland-Cliffs, and Aurora Cannabis Jumped Today | ACB | https://www.nasdaq.com/articles/why-okta-cleveland-cliffs-and-aurora-cannabis-jumped-today-2019-10-03 | nan | nan | The stock market managed to regain a bit of ground Thursday, recovering from an early drop as investors continued to try to parse through the many uncertainties facing them on the macroeconomic and geopolitical fronts. Gains for major benchmarks were as high as 1%, but a few companies managed to see even stronger moves... | Okta (NASDAQ: OKTA), Cleveland-Cliffs (NYSE: CLF), and Aurora Cannabis (NYSE: ACB) were among the top performers. The stock market managed to regain a bit of ground Thursday, recovering from an early drop as investors continued to try to parse through the many uncertainties facing them on the macroeconomic and geopolit... | Okta (NASDAQ: OKTA), Cleveland-Cliffs (NYSE: CLF), and Aurora Cannabis (NYSE: ACB) were among the top performers. The marijuana cultivator told investors today that its global production facility construction projects had achieved important milestones, including its Aurora Sun growth facility in Alberta, its Nordic Sky... | Okta (NASDAQ: OKTA), Cleveland-Cliffs (NYSE: CLF), and Aurora Cannabis (NYSE: ACB) were among the top performers. The marijuana cultivator told investors today that its global production facility construction projects had achieved important milestones, including its Aurora Sun growth facility in Alberta, its Nordic Sky... | Okta (NASDAQ: OKTA), Cleveland-Cliffs (NYSE: CLF), and Aurora Cannabis (NYSE: ACB) were among the top performers. High times for Aurora Finally, shares of Aurora Cannabis picked up 9%. In fact, the newsletter they run, Motley Fool Stock Advisor, has quadrupled the S&P 500! |
38072.0 | 2019-10-03 00:00:00 UTC | Health Care Sector Update for 10/03/2019: MIST,ACB,ACB.TO,OBLN,MESO | ACB | https://www.nasdaq.com/articles/health-care-sector-update-for-10-03-2019%3A-mistacbacb.tooblnmeso-2019-10-03 | nan | nan | Top Health Care Stocks
JNJ -0.90%
PFE +1.95%
ABT +1.68%
MRK +1.10%
AMGN +1.52%
Health care stocks still were mostly higher, with the NYSE Health Care Index in Thursday trade rising almost 0.7% while the shares of health care companies in the S&P 500 also were up nearly 0.7% as a group. The Nasdaq Biotechnology index wa... | (+) Aurora Cannabis (ACB) was nearly 9% higher late Thursday after the Canadian medical and recreational marijuana company said its Agroprop subsidiary is now harvesting around 9,000 acres of hemp in Lithuania, Latvia and Estonia for processing at its drying facility in Kaunas, Lithuania. Among health care stocks movin... | (+) Aurora Cannabis (ACB) was nearly 9% higher late Thursday after the Canadian medical and recreational marijuana company said its Agroprop subsidiary is now harvesting around 9,000 acres of hemp in Lithuania, Latvia and Estonia for processing at its drying facility in Kaunas, Lithuania. Top Health Care Stocks Health ... | (+) Aurora Cannabis (ACB) was nearly 9% higher late Thursday after the Canadian medical and recreational marijuana company said its Agroprop subsidiary is now harvesting around 9,000 acres of hemp in Lithuania, Latvia and Estonia for processing at its drying facility in Kaunas, Lithuania. Health care stocks still were ... | (+) Aurora Cannabis (ACB) was nearly 9% higher late Thursday after the Canadian medical and recreational marijuana company said its Agroprop subsidiary is now harvesting around 9,000 acres of hemp in Lithuania, Latvia and Estonia for processing at its drying facility in Kaunas, Lithuania. Health care stocks still were ... |
38073.0 | 2019-10-03 00:00:00 UTC | Health Care Sector Update for 10/03/2019: ACB,OBLN,MESO | ACB | https://www.nasdaq.com/articles/health-care-sector-update-for-10-03-2019%3A-acboblnmeso-2019-10-03 | nan | nan | Top Health Care Stocks
JNJ -0.58%
PFE +1.24%
ABT +1.72%
MRK +1.11%
AMGN +1.67%
Health care stocks were mostly higher, including a nearly 0.7% gain for the NYSE Health Care Index in Thursday trade while the shares of health care companies in the S&P 500 also were up more than 0.6% as a group. The Nasdaq Biotechnology in... | Among health care stocks moving on news: (+) Aurora Cannabis (ACB) rose 4% on Thursday after the Canadian medical and recreational marijuana company said its Agroprop subsidiary is now harvesting around 9,000 acres of hemp in Lithuania, Latvia and Estonia for processing at its drying facility in Kaunas, Lithuania. Its ... | Among health care stocks moving on news: (+) Aurora Cannabis (ACB) rose 4% on Thursday after the Canadian medical and recreational marijuana company said its Agroprop subsidiary is now harvesting around 9,000 acres of hemp in Lithuania, Latvia and Estonia for processing at its drying facility in Kaunas, Lithuania. Top ... | Among health care stocks moving on news: (+) Aurora Cannabis (ACB) rose 4% on Thursday after the Canadian medical and recreational marijuana company said its Agroprop subsidiary is now harvesting around 9,000 acres of hemp in Lithuania, Latvia and Estonia for processing at its drying facility in Kaunas, Lithuania. Heal... | Among health care stocks moving on news: (+) Aurora Cannabis (ACB) rose 4% on Thursday after the Canadian medical and recreational marijuana company said its Agroprop subsidiary is now harvesting around 9,000 acres of hemp in Lithuania, Latvia and Estonia for processing at its drying facility in Kaunas, Lithuania. Top ... |
38074.0 | 2019-10-03 00:00:00 UTC | Avoid Canopy Growth Stock Until This One Thing Happens | ACB | https://www.nasdaq.com/articles/avoid-canopy-growth-stock-until-this-one-thing-happens-2019-10-03 | nan | nan | Analysts continue to speak in increasingly glowing terms about Canopy Growth’s (NYSE:) long-term future. However, Canopy Growth stock has been sliding downward since April.
Source: Jarretera / Shutterstock.com
The U.S. recommends more research and standardization before cannabis edibles are legalized. Despite this war... | The huge investment that CGC received from Constellation Brands (NYSE:) bodes well for its finances and for its ability to overcome challenges in areas such as marketing and distribution. Piper Jaffray analyst Michael Lavery credited Canopy Growth as having “” even after he trimmed his target price on CGC stock from $... | Analysts continue to speak in increasingly glowing terms about Canopy Growth’s (NYSE:) long-term future. The Bottom Line on Canopy Growth Stock Investors should avoid CGC stock until a positive catalyst shows signs of taking the shares higher. Analysts speak in increasingly glowing terms about the long-term outlook of... | Although cannabis derivatives could become a needed positive catalyst for marijuana stocks, investors should stay away from CGC as long as the stock continues to fall. The Retreat of CGC Stock Is Continuing Still, sentiment towards Canopy Growth stock has not improved. The Bottom Line on Canopy Growth Stock Investors ... | Although cannabis derivatives could become a needed positive catalyst for marijuana stocks, investors should stay away from CGC as long as the stock continues to fall. The Retreat of CGC Stock Is Continuing Still, sentiment towards Canopy Growth stock has not improved. For that reason, investors should, for now, watch... |
38075.0 | 2019-10-03 00:00:00 UTC | Interesting ACB Put And Call Options For November 22nd | ACB | https://www.nasdaq.com/articles/interesting-acb-put-and-call-options-for-november-22nd-2019-10-03 | nan | nan | Investors in Aurora Cannabis Inc (Symbol: ACB) saw new options become available today, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACB options chain for the new November 22nd contracts and identified one put and one call contract of particular interest.
... | Of course, a lot of upside could potentially be left on the table if ACB shares really soar, which is why looking at the trailing twelve month trading history for Aurora Cannabis Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACB's trailing twelve month trading history, w... | Below is a chart showing ACB's trailing twelve month trading history, with the $5.00 strike highlighted in red: Considering the fact that the $5.00 strike represents an approximate 18% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibi... | Below is a chart showing ACB's trailing twelve month trading history, with the $5.00 strike highlighted in red: Considering the fact that the $5.00 strike represents an approximate 18% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibi... | At Stock Options Channel, our YieldBoost formula has looked up and down the ACB options chain for the new November 22nd contracts and identified one put and one call contract of particular interest. Below is a chart showing ACB's trailing twelve month trading history, with the $5.00 strike highlighted in red: Consideri... |
38076.0 | 2019-10-03 00:00:00 UTC | Should Contrarian Investors Buy Aurora Cannabis Stock in October? | ACB | https://www.nasdaq.com/articles/should-contrarian-investors-buy-aurora-cannabis-stock-in-october-2019-10-03 | nan | nan | Editor’s Note: This story was updated on Oct. 3, 2019, to correct Aurora Cannabis stock’s 52-week low price.
On Sept. 11, Alberta-based Aurora Cannabis (NYSE:) released fourth-quarter and fiscal 2019 results that disappointed investors. Yet earlier in August, ACB stock had already decreased its revenue forecast.
Sourc... | Yet earlier in August, ACB stock had already decreased its revenue forecast. Source: Shutterstock So when ACB stock missed the low end of its own guidance, Wall Street held the company accountable for the miss. ACB stock’s net loss came at $2.3 million CAD on net revenue of $98.9 million CAD, with an adjusted EBITDA lo... | ACB stock’s net loss came at $2.3 million CAD on net revenue of $98.9 million CAD, with an adjusted EBITDA loss of $11.7 million CAD. Yet earlier in August, ACB stock had already decreased its revenue forecast. Source: Shutterstock So when ACB stock missed the low end of its own guidance, Wall Street held the company a... | ACB stock’s disappointing earnings follow several other poor results from large Canadian cannabis companies. Yet earlier in August, ACB stock had already decreased its revenue forecast. Source: Shutterstock So when ACB stock missed the low end of its own guidance, Wall Street held the company accountable for the miss. | Yet earlier in August, ACB stock had already decreased its revenue forecast. Source: Shutterstock So when ACB stock missed the low end of its own guidance, Wall Street held the company accountable for the miss. ACB stock’s net loss came at $2.3 million CAD on net revenue of $98.9 million CAD, with an adjusted EBITDA lo... |
38077.0 | 2019-10-03 00:00:00 UTC | Marijuana Stock Goodwill Is a Potential $10 Billion Powder Keg | ACB | https://www.nasdaq.com/articles/marijuana-stock-goodwill-is-a-potential-%2410-billion-powder-keg-2019-10-03 | nan | nan | Few industries offer as much long-term promise as legal cannabis. After worldwide sales of legal weed more than tripled between 2014 and 2018, independent researchers Arcview Market Research and BDS Analytics have forecast a near-quadrupling in global sales through 2024 to north of $40 billion. Beyond that, Wall Street... | Aurora Cannabis (NYSE: ACB), for example, has made more than a dozen acquisitions over the past three years. With the marijuana industry expected to grow at a rapid clip, North American pot stocks have aggressively been buying smaller businesses in order to boost production capacity, broaden their portfolio offerings, ... | Aurora Cannabis (NYSE: ACB), for example, has made more than a dozen acquisitions over the past three years. With the marijuana industry expected to grow at a rapid clip, North American pot stocks have aggressively been buying smaller businesses in order to boost production capacity, broaden their portfolio offerings, ... | Aurora Cannabis (NYSE: ACB), for example, has made more than a dozen acquisitions over the past three years. From these three marijuana stocks, plus Tilray and its $155 million in goodwill from the purchase of Manitoba Harvest, the industry has racked up more than $4.5 billion in goodwill (when converted to U.S. dollar... | Aurora Cannabis (NYSE: ACB), for example, has made more than a dozen acquisitions over the past three years. Origin House, for instance, ended June with CA$258.8 million in total assets, of which CA$83 million was goodwill and CA$60.2 million was intangible assets. Here's The Marijuana Stock You've Been Waiting For A l... |
38078.0 | 2019-10-03 00:00:00 UTC | Vape Sales are Falling: Why this Could Be Bad News for Canadian Cannabis Companies | ACB | https://www.nasdaq.com/articles/vape-sales-are-falling%3A-why-this-could-be-bad-news-for-canadian-cannabis-companies-2019-10 | nan | nan | Vaping has been making news for all the wrong reasons lately. It has made more than 800 people sick, and 16 have died from related illnesses, according to the latest numbers from the New York Times. While there's speculation that the real culprit is a result of vitamin E and that the problem is originating from the bl... | Earlier this year, four cannabis companies, including Aurora Cannabis (NYSE: ACB), secured deals with vaping company Pax Labs to supply cannabis extracts that would be used in Pax's popular vaping system. While there's speculation that the real culprit is a result of vitamin E and that the problem is originating from t... | Earlier this year, four cannabis companies, including Aurora Cannabis (NYSE: ACB), secured deals with vaping company Pax Labs to supply cannabis extracts that would be used in Pax's popular vaping system. And that could be a big problem for Canadian cannabis companies looking forward to the launch of cannabis-derivativ... | Earlier this year, four cannabis companies, including Aurora Cannabis (NYSE: ACB), secured deals with vaping company Pax Labs to supply cannabis extracts that would be used in Pax's popular vaping system. Canadian companies were expecting big things from vaping According to data from the BCMI Cannabis Report, it was es... | Earlier this year, four cannabis companies, including Aurora Cannabis (NYSE: ACB), secured deals with vaping company Pax Labs to supply cannabis extracts that would be used in Pax's popular vaping system. Canadian companies were expecting big things from vaping According to data from the BCMI Cannabis Report, it was es... |
38079.0 | 2019-10-02 00:00:00 UTC | Aphria Stock Should Thrive Regardless of Vaping Regulations | ACB | https://www.nasdaq.com/articles/aphria-stock-should-thrive-regardless-of-vaping-regulations-2019-10-02 | nan | nan | Aphria (NYSE:) stock had a brutal September. The controversy surrounding vaping led investors to dump APHA stock because the company had made a significant investment in this area.
Source: Shutterstock
Investigators have not yet determined what caused the illnesses and deaths that appear to have been linked to vaping.... | The controversy surrounding vaping led investors to dump APHA stock because the company had made a significant investment in this area. Source: Shutterstock Investigators have not yet determined what caused the illnesses and deaths that appear to have been linked to vaping. Such warnings cause harm to not only Aphria ... | InvestorPlace columnist Luke Lango goes further, pointing out that the company’s cost-cutting has given APHA stock the However, investors’ primary concern about Aphria stock now involves vaping, a segment in which Aphria has invested heavily. Experts do not know whether THC-based products, nicotine, or illegal vaping p... | Vaping Has Weighed on Aphria Stock Until recently, I owned Aphria stock. InvestorPlace columnist Luke Lango goes further, pointing out that the company’s cost-cutting has given APHA stock the However, investors’ primary concern about Aphria stock now involves vaping, a segment in which Aphria has invested heavily. Alth... | Given Aphria’s lead in other segments, APHA should weather this storm over the long-term, ultimately turning the recent drop of APHA stock into a great buying opportunity. Vaping Has Weighed on Aphria Stock Until recently, I owned Aphria stock. Moreover, it has become the first major cannabis company to earn a profit, ... |
38080.0 | 2019-10-02 00:00:00 UTC | 7 Marijuana Stocks With Critical Levels to Watch | ACB | https://www.nasdaq.com/articles/7-marijuana-stocks-with-critical-levels-to-watch-2019-10-02 | nan | nan | [Editor’s note: This story will be updated each week with new stocks and analysis. Please check back often for Mark’s latest take on marijuana stocks.]
In financial markets there are certain levels that are more important than others with regards to the amount of supply and demand that exists. Additionally, in financia... | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is a Canadian-based company that grows and sells medical marijuana, indoor cultivation systems, and hemp-related food products. After a weak earnings report and some analyst downgrades, ACB stock has been in a free-fall over the past three weeks. ACB stock is oversold so th... | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is a Canadian-based company that grows and sells medical marijuana, indoor cultivation systems, and hemp-related food products. After a weak earnings report and some analyst downgrades, ACB stock has been in a free-fall over the past three weeks. ACB stock is oversold so th... | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is a Canadian-based company that grows and sells medical marijuana, indoor cultivation systems, and hemp-related food products. After a weak earnings report and some analyst downgrades, ACB stock has been in a free-fall over the past three weeks. ACB stock is oversold so th... | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) is a Canadian-based company that grows and sells medical marijuana, indoor cultivation systems, and hemp-related food products. After a weak earnings report and some analyst downgrades, ACB stock has been in a free-fall over the past three weeks. ACB stock is oversold so th... |
38081.0 | 2019-10-02 00:00:00 UTC | Forget $4: Aurora Cannabis Could Drop Below $3 | ACB | https://www.nasdaq.com/articles/forget-%244%3A-aurora-cannabis-could-drop-below-%243-2019-10-02 | nan | nan | Just nine days ago, I opined that it was reasonable to expect that the largest marijuana producer in the world, Aurora Cannabis (NYSE: ACB), might fall below $4 a share – a price point that seemed unimaginable with the company's stock lapping at $10 just six months prior. But in just over a week's time, Aurora is dange... | Just nine days ago, I opined that it was reasonable to expect that the largest marijuana producer in the world, Aurora Cannabis (NYSE: ACB), might fall below $4 a share – a price point that seemed unimaginable with the company's stock lapping at $10 just six months prior. Part of this shortage can very well be blamed o... | Just nine days ago, I opined that it was reasonable to expect that the largest marijuana producer in the world, Aurora Cannabis (NYSE: ACB), might fall below $4 a share – a price point that seemed unimaginable with the company's stock lapping at $10 just six months prior. Between June 2014 and June 2019, Aurora's outst... | Just nine days ago, I opined that it was reasonable to expect that the largest marijuana producer in the world, Aurora Cannabis (NYSE: ACB), might fall below $4 a share – a price point that seemed unimaginable with the company's stock lapping at $10 just six months prior. Aurora takes a substantial goodwill writedown M... | Just nine days ago, I opined that it was reasonable to expect that the largest marijuana producer in the world, Aurora Cannabis (NYSE: ACB), might fall below $4 a share – a price point that seemed unimaginable with the company's stock lapping at $10 just six months prior. Over the past three years, the company has made... |
38082.0 | 2019-10-01 00:00:00 UTC | Marijuana Stocks Hit 1-Year Lows | ACB | https://www.nasdaq.com/articles/marijuana-stocks-hit-1-year-lows-2019-10-01 | nan | nan | A clutch of marijuana stocks have hit their one-year bottoms. Top players Aurora Cannabis (NYSE: ACB), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) all reached that dubious milestone at market close on Tuesday after doing so on Monday as well.
Although there was little company-specific news during either day th... | Top players Aurora Cannabis (NYSE: ACB), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) all reached that dubious milestone at market close on Tuesday after doing so on Monday as well. Shortly previous to that, Oppenheimer launched coverage of Canopy Growth stock with a tepid perform (i.e., neutral) recommendation... | Top players Aurora Cannabis (NYSE: ACB), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) all reached that dubious milestone at market close on Tuesday after doing so on Monday as well. Last week, for example, Bank of America cut its recommendation on Canopy Growth -- a bellwether stock in the sector -- from buy to... | Top players Aurora Cannabis (NYSE: ACB), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) all reached that dubious milestone at market close on Tuesday after doing so on Monday as well. Shortly previous to that, Oppenheimer launched coverage of Canopy Growth stock with a tepid perform (i.e., neutral) recommendation... | Top players Aurora Cannabis (NYSE: ACB), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) all reached that dubious milestone at market close on Tuesday after doing so on Monday as well. Many government and cannabis business pundits feel the Senate will not pass either a version of the SAFE Banking Act or similar le... |
38083.0 | 2019-10-01 00:00:00 UTC | Why TD Ameritrade, Bausch Health, and Aurora Cannabis Slumped Today | ACB | https://www.nasdaq.com/articles/why-td-ameritrade-bausch-health-and-aurora-cannabis-slumped-today-2019-10-01 | nan | nan | Tuesday was a bad day on Wall Street, with investors struggling through a downbeat assessment of the likely path of the manufacturing economy for the foreseeable future. Major indexes suffered losses of more than 1%, casting a shadow over the beginning of the fourth quarter of what until now has been a strong year for ... | TD Ameritrade (NASDAQ: AMTD), Bausch Health (NYSE: BHC), and Aurora Cannabis (NYSE: ACB) were among the worst performers. With most people figuring that the entire industry will have to follow Schwab's lead in the long run, the move lower for TD Ameritrade reflects the financial hit that it will likely suffer in the ne... | TD Ameritrade (NASDAQ: AMTD), Bausch Health (NYSE: BHC), and Aurora Cannabis (NYSE: ACB) were among the worst performers. Broker wars hurt TD Ameritrade Shares of TD Ameritrade plunged 26% after the brokerage company faced a competitive onslaught from one of its biggest rivals. In fact, the newsletter they run, Motley ... | TD Ameritrade (NASDAQ: AMTD), Bausch Health (NYSE: BHC), and Aurora Cannabis (NYSE: ACB) were among the worst performers. Broker wars hurt TD Ameritrade Shares of TD Ameritrade plunged 26% after the brokerage company faced a competitive onslaught from one of its biggest rivals. Bausch heads for litigation Bausch Health... | TD Ameritrade (NASDAQ: AMTD), Bausch Health (NYSE: BHC), and Aurora Cannabis (NYSE: ACB) were among the worst performers. Offer from The Motley Fool: The 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Foo... |
38084.0 | 2019-10-01 00:00:00 UTC | Hexo Stock Is Cheap on a Forward Basis—but Success Is Not Guaranteed | ACB | https://www.nasdaq.com/articles/hexo-stock-is-cheap-on-a-forward-basis-but-success-is-not-guaranteed-2019-10-01 | nan | nan | Hexo (NYSE:) stock has traded sideways since my last analysis on Aug. 30. Shares currently trade at the $4 price level. The Hexo stock price is down more than 50% from its 52-week high of $8.40/share set in May.
Source: Shutterstock
Like other names in the “cannabisphere,” investor expectations have been blunted by sho... | As the United States market has yet to fully open up, investors are betting on future, not present performance. Potential partners include big names in cosmetics, pharmaceuticals, food products, and vaping. However, MKM Partners’s Bill Kirk doesn’t believe the market is giving Hexo for their 2020 sales projections. | HEXO Stock on Track with Truss The company is on track to launch infused beverage Truss with partner Molson Coors (NYSE:) in December, when infused beverages and edibles become legal across Canada. Hexo missed its last quarterly sales estimate ($9.76 million actual vs. $10.8 million analyst estimate). Hexo Stock Price ... | HEXO Stock on Track with Truss The company is on track to launch infused beverage Truss with partner Molson Coors (NYSE:) in December, when infused beverages and edibles become legal across Canada. Unlike Canopy Growth, which has slowly ceded control to partner Constellation Brands (NYSE:), Molson Coors owns very few (... | HEXO Stock on Track with Truss The company is on track to launch infused beverage Truss with partner Molson Coors (NYSE:) in December, when infused beverages and edibles become legal across Canada. Unlike Canopy Growth, which has slowly ceded control to partner Constellation Brands (NYSE:), Molson Coors owns very few (... |
38085.0 | 2019-10-01 00:00:00 UTC | 2 Pot Stocks That Are Better Buys Than Aurora Cannabis | ACB | https://www.nasdaq.com/articles/2-pot-stocks-that-are-better-buys-than-aurora-cannabis-2019-10-01 | nan | nan | Aurora Cannabis (NYSE: ACB) may be one of the largest marijuana stocks you can invest in, but that doesn't mean it's one of the best. While the company has been continuing to grow its revenues at an impressive pace, rising expenses have prevented the company from getting to breakeven. In its most recent fiscal year, Au... | Aurora Cannabis (NYSE: ACB) may be one of the largest marijuana stocks you can invest in, but that doesn't mean it's one of the best. The company doesn't have a big advantage over its rivals, and at a market cap of close to $4.5 billion, it's also one of the most expensive pot stocks that investors can buy today. And i... | Aurora Cannabis (NYSE: ACB) may be one of the largest marijuana stocks you can invest in, but that doesn't mean it's one of the best. In its most recent fiscal year, Aurora's net losses totaled $298 million Canadian dollars. Green Thumb Industries Green Thumb Industries (OTC: GTBIF) doesn't have a big global reach, but... | Aurora Cannabis (NYSE: ACB) may be one of the largest marijuana stocks you can invest in, but that doesn't mean it's one of the best. The company doesn't have a big advantage over its rivals, and at a market cap of close to $4.5 billion, it's also one of the most expensive pot stocks that investors can buy today. And w... | Aurora Cannabis (NYSE: ACB) may be one of the largest marijuana stocks you can invest in, but that doesn't mean it's one of the best. The company doesn't have a big advantage over its rivals, and at a market cap of close to $4.5 billion, it's also one of the most expensive pot stocks that investors can buy today. Simpl... |
38086.0 | 2019-10-01 00:00:00 UTC | The Tables Could Soon Turn Back in Favor of Tilray Stock | ACB | https://www.nasdaq.com/articles/the-tables-could-soon-turn-back-in-favor-of-tilray-stock-2019-10-01 | nan | nan | The past year hasn’t been kind to Tilray (NASDAQ:) investors. TLRY stock is down a stunning 84% since this point in time in 2018. As it turns out, existing in the cannabis space isn’t a guarantee of profits. And, it’s also reasonably safe to say excessive hype set most of the big names up for even bigger falls.
Source:... | Less Production, More Retailing Tilray CEO Brendan Kennedy has alluded to this idea before, but he made a point of highlighting it during August’s second-quarter conference call. “… and we’ve signed long-term wholesale supply agreements to support our cultivation asset-light model and enable us to focus on the cannabis... | That’s in sharp contrast to rival cannabis companies like Canopy Growth (NYSE:), which has been adding growing acreage at a brisk clip. Aurora Cannabis (NYSE:), meanwhile, remains the growth leader, producing roughly 150,000 kilograms of cannabis per year now. But, given that so many marijuana names have already commit... | In turn, the company can offer pot products at lower prices than many of its rivals can — rivals that paid steep prices for production capacity. Bottom Line for Tilray Stock In May, Kennedy conceded that in ten years he wants Tilray to of the industry’s product. Given the looming boom in supply though, the company coul... | A closer look at the industry’s supply and demand dynamics suggests supply isn’t a problem. Bottom Line for Tilray Stock In May, Kennedy conceded that in ten years he wants Tilray to of the industry’s product. But, given that so many marijuana names have already committed time and money to production capacity when pot ... |
38087.0 | 2019-09-30 00:00:00 UTC | Why Cronos Group Is Overvalued Right Now | ACB | https://www.nasdaq.com/articles/why-cronos-group-is-overvalued-right-now-2019-09-30 | nan | nan | The majority of cannabis stocks have seen their shares plummet over the past few months, eradicating most of the earlier gains seen in the first quarter of 2019. While many of these companies have become viable investment opportunities now that they're trading at lower prices, there is still a handful of stocks I would... | The company has recently overtaken Tilray (NASDAQ: TLRY) as the third-largest cannabis company by market cap, behind only Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Unlike other producers, Cronos has very few assets in Canada; instead, it has focused on expanding in the U.S. One of the more recent devel... | The company has recently overtaken Tilray (NASDAQ: TLRY) as the third-largest cannabis company by market cap, behind only Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Cronos Group is trading at 114.6 times enterprise value to sales based on its recent quarterly financial data. Here's a comparison of major... | The company has recently overtaken Tilray (NASDAQ: TLRY) as the third-largest cannabis company by market cap, behind only Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). The difference between Tilray and Cronos now, however, is that Tilray is currently trading at a much more reasonable multiple, only 25.9 ti... | The company has recently overtaken Tilray (NASDAQ: TLRY) as the third-largest cannabis company by market cap, behind only Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Cronos Group is trading at 114.6 times enterprise value to sales based on its recent quarterly financial data. Here's a comparison of major... |
38088.0 | 2019-09-30 00:00:00 UTC | 2 Marijuana Stocks to Flat-Out Avoid in the Fourth Quarter | ACB | https://www.nasdaq.com/articles/2-marijuana-stocks-to-flat-out-avoid-in-the-fourth-quarter-2019-09-30 | nan | nan | Marijuana stocks kicked off 2019 on a strong note, but most of the industry's top names have been in free fall ever since the end of the first quarter. The legal cannabis industry has been bleeding value as the year has progressed for a variety of reasons, including several high-profile scandals, middle-of-the-road ear... | For instance, Aurora Cannabis (NYSE: ACB) and Tilray (NASDAQ: TLRY) both seem to be headed for a particularly rough fourth quarter from a share performance standpoint. The legal cannabis industry has been bleeding value as the year has progressed for a variety of reasons, including several high-profile scandals, middle... | For instance, Aurora Cannabis (NYSE: ACB) and Tilray (NASDAQ: TLRY) both seem to be headed for a particularly rough fourth quarter from a share performance standpoint. Aurora Cannabis is a falling knife Aurora was one of the hottest pot stocks during the first quarter of 2019, with its shares gaining an astounding 82.6... | For instance, Aurora Cannabis (NYSE: ACB) and Tilray (NASDAQ: TLRY) both seem to be headed for a particularly rough fourth quarter from a share performance standpoint. Aurora Cannabis is a falling knife Aurora was one of the hottest pot stocks during the first quarter of 2019, with its shares gaining an astounding 82.6... | For instance, Aurora Cannabis (NYSE: ACB) and Tilray (NASDAQ: TLRY) both seem to be headed for a particularly rough fourth quarter from a share performance standpoint. Aurora Cannabis is a falling knife Aurora was one of the hottest pot stocks during the first quarter of 2019, with its shares gaining an astounding 82.6... |
38089.0 | 2019-09-30 00:00:00 UTC | Canopy Growth Emerges as Top ‘Cannabis 2.0’ Stock | ACB | https://www.nasdaq.com/articles/canopy-growth-emerges-as-top-cannabis-2.0-stock-2019-09-30 | nan | nan | Canadian cannabis leader Canopy Growth Corporation (NYSE:) exploded over the past two years, from a low point of around $5 in 2017 to $57 in late 2018. However, CGC stock now trades nearly 60% lower than its high, at $23.83 a share. All as investors lost confidence with a spate of lousy industry hiccups, the dismissal ... | In fact, after initiating coverage of Canopy Growth with a “perform” rating, he warned CGC is facing over $500 million in bottom-line losses in the two-year period ending March 2021. Bank of America analysts also cut their coverage of the stock to “neutral” from a “buy” rating, concerned that growth in key Canadian mar... | Canadian cannabis leader Canopy Growth Corporation (NYSE:) exploded over the past two years, from a low point of around $5 in 2017 to $57 in late 2018. Canopy Growth Has Fallen on Hard Times Canopy Growth fell in recent weeks after Oppenheimer analyst Rupesh Parikh warned that investors should brace for bigger losses i... | Canopy Growth Has Fallen on Hard Times Canopy Growth fell in recent weeks after Oppenheimer analyst Rupesh Parikh warned that investors should brace for bigger losses in the next two years. Yet, when access to cannabis for medical purposes is combined with demand-side regulations (namely, DSLs) we observe a decrease in... | Two, the analyst was encouraged by Constellation Brand’s (NYSE:) $4 billion cash infusion, and the company’s sizable footprint in Canada’s cannabis market. The Bottom Line for CGC Stock While a 60% drop in the CGC stock is stomach-churning, it appears the market has become far too negative with a lousy market environme... |
38090.0 | 2019-09-30 00:00:00 UTC | This Cannabis ETF Gives Investors a New Way to Profit From the Marijuana Market's Torrid Growth | ACB | https://www.nasdaq.com/articles/this-cannabis-etf-gives-investors-a-new-way-to-profit-from-the-marijuana-markets-torrid | nan | nan | Cannabis could become a $200 billion industry within the next decade, according to investment bank Stifel, up from $12 billion in 2018. Now, there's a new way to claim your share of this megatrend: the Global X Cannabis ETF (Nasdaq: POTX).
The exchange-traded fund launched on Sept. 19. It aims to provide a simple, low-... | Top holdings include Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and HEXO (NYSE: HEXO). "Cannabis provides a unique opportunity to access a trend in its nascent stages, driven by advancements in medicinal and industrial uses, but with further upside potential given increasing efforts to legalize recreationa... | Top holdings include Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and HEXO (NYSE: HEXO). Now, there's a new way to claim your share of this megatrend: the Global X Cannabis ETF (Nasdaq: POTX). The Global X Cannabis ETF can help you profit from the cannabis boom. | Top holdings include Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and HEXO (NYSE: HEXO). The Global X Cannabis ETF can help you profit from the cannabis boom. The ETF tracks the Cannabis Index, which includes companies that derive at least half of their sales, profits, or assets from cannabis. | Top holdings include Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and HEXO (NYSE: HEXO). The Global X Cannabis ETF can help you profit from the cannabis boom. The fund's fees are relatively low at 0.50%, or 50% per $10,000 invested per year, which makes it the least expensive passively managed cannabis ETF i... |
38091.0 | 2019-09-29 00:00:00 UTC | 2 Penny Marijuana Stocks to Buy in the 4th Quarter | ACB | https://www.nasdaq.com/articles/2-penny-marijuana-stocks-to-buy-in-the-4th-quarter-2019-09-29 | nan | nan | After a red-hot start to the year, marijuana stocks were taken to the woodshed in the third quarter of 2019. Top names like Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Tilray (NASDAQ: TLRY) all lost a significant amount of their value over the past three months, thanks to a slew of headwinds such as hea... | Top names like Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Tilray (NASDAQ: TLRY) all lost a significant amount of their value over the past three months, thanks to a slew of headwinds such as health concerns over vaping, managerial instability, scandals, and an increasingly risk-averse market. The real ... | Top names like Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Tilray (NASDAQ: TLRY) all lost a significant amount of their value over the past three months, thanks to a slew of headwinds such as health concerns over vaping, managerial instability, scandals, and an increasingly risk-averse market. The penny... | Top names like Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Tilray (NASDAQ: TLRY) all lost a significant amount of their value over the past three months, thanks to a slew of headwinds such as health concerns over vaping, managerial instability, scandals, and an increasingly risk-averse market. The penny... | Top names like Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Tilray (NASDAQ: TLRY) all lost a significant amount of their value over the past three months, thanks to a slew of headwinds such as health concerns over vaping, managerial instability, scandals, and an increasingly risk-averse market. The penny... |
38092.0 | 2019-09-29 00:00:00 UTC | 3 Marijuana Stocks to Be Especially Leery About Buying Right Now | ACB | https://www.nasdaq.com/articles/3-marijuana-stocks-to-be-especially-leery-about-buying-right-now-2019-09-29 | nan | nan | Don't think that the broad pullback for marijuana stocks means doom and gloom is here to stay for the industry. Investors in marijuana stocks have become accustomed to big swings both up and down. An upturn will arrive sooner or later.
However, not every marijuana stock is a smart pick to buy right now. I think investo... | I think investors should be especially leery about three stocks: Aurora Cannabis (NYSE: ACB), CannTrust Holdings (NYSE: CTST), and Tilray (NASDAQ: TLRY). But the Canadian cannabis producer quickly went from darling to downgrades after it managed to miss fourth-quarter revenue guidance that it had provided only a few we... | I think investors should be especially leery about three stocks: Aurora Cannabis (NYSE: ACB), CannTrust Holdings (NYSE: CTST), and Tilray (NASDAQ: TLRY). Aurora Cannabis Aurora Cannabis was a darling of Wall Street analysts earlier this year. The company continues to reel from the disclosure earlier this year that it c... | I think investors should be especially leery about three stocks: Aurora Cannabis (NYSE: ACB), CannTrust Holdings (NYSE: CTST), and Tilray (NASDAQ: TLRY). Aurora Cannabis Aurora Cannabis was a darling of Wall Street analysts earlier this year. There are better marijuana stocks to buy without nearly as much baggage as th... | I think investors should be especially leery about three stocks: Aurora Cannabis (NYSE: ACB), CannTrust Holdings (NYSE: CTST), and Tilray (NASDAQ: TLRY). With Aurora maintaining that it doesn't want an equity investment from a big partner outside the cannabis industry, it needs to make progress on its path to profitabi... |
38093.0 | 2019-09-29 00:00:00 UTC | Will the Big Canadian Pot Producers Miss Expectations Again? | ACB | https://www.nasdaq.com/articles/will-the-big-canadian-pot-producers-miss-expectations-again-2019-09-29 | nan | nan | It's been a rough 12 months for Canada's licensed cannabis producers, but at least investors can still look forward to next year. Consensus estimates for Canadian licensed marijuana sales are expected to reach CA$6.5 billion in 2020 and climb to CA$7.5 billion in 2021.
A recent note to investors from John Zapparo at th... | Gaining market share Canada effectively decriminalized cannabis possession a long time ago, and the internet is rife with mail-order marijuana services that sell higher-quality products at significantly lower prices. Trouble ahead Unfortunately for the industry, per-gram prices aren't likely to stay aloft because the b... | Consensus estimates for Canadian licensed marijuana sales are expected to reach CA$6.5 billion in 2020 and climb to CA$7.5 billion in 2021. More retail locations and an improved supply chain have been helping licensed cannabis gain market share, but the illicit market isn't giving in easily. During the three months end... | Consensus estimates for Canadian licensed marijuana sales are expected to reach CA$6.5 billion in 2020 and climb to CA$7.5 billion in 2021. If we include Tilray (NASDAQ: TLRY), which reports in U.S. dollars, and fiscal 2021 estimates that aren't available yet for Sundial and Hexo, CIBC's predictions for licensed Canadi... | Consensus estimates for Canadian licensed marijuana sales are expected to reach CA$6.5 billion in 2020 and climb to CA$7.5 billion in 2021. If licensed cannabis sales are going to reach the consensus estimate of CA$6.5 billion in 2020, they'll have to sell around 1.05 million kilogram equivalents at recent prices. In 2... |
38094.0 | 2019-09-29 00:00:00 UTC | Aurora Cannabis' Ticking Time Bomb | ACB | https://www.nasdaq.com/articles/aurora-cannabis-ticking-time-bomb-2019-09-29 | nan | nan | It's been a wild ride for Aurora Cannabis (NYSE: ACB) so far this year. Analysts came out of the woodwork to recommend the stock early in 2019.
Aurora delivered sizzling revenue growth quarter after quarter. It brought billionaire investor Nelson Peltz on board to help line up partners from outside the cannabis industr... | It's been a wild ride for Aurora Cannabis (NYSE: ACB) so far this year. Also, the Cannabis 2.0 market won't have a significant financial impact on Aurora until the company reports its fiscal 2020 Q3 results -- and that will be after the looming convertible debentures maturity date. That leaves Aurora with three primary... | It's been a wild ride for Aurora Cannabis (NYSE: ACB) so far this year. Aurora has 230 million in Canadian dollars worth of convertible debentures that mature in March 2020. Also, the Cannabis 2.0 market won't have a significant financial impact on Aurora until the company reports its fiscal 2020 Q3 results -- and that... | It's been a wild ride for Aurora Cannabis (NYSE: ACB) so far this year. Also, the Cannabis 2.0 market won't have a significant financial impact on Aurora until the company reports its fiscal 2020 Q3 results -- and that will be after the looming convertible debentures maturity date. Aurora's alternatives The odds appear... | It's been a wild ride for Aurora Cannabis (NYSE: ACB) so far this year. Maybe the "Cannabis 2.0" cannabis derivatives market that launches soon could provide a major catalyst for Aurora. Also, the Cannabis 2.0 market won't have a significant financial impact on Aurora until the company reports its fiscal 2020 Q3 result... |
38095.0 | 2019-09-28 00:00:00 UTC | The First Tradable Cannabis ETF Has Now Lost Half Its Value | ACB | https://www.nasdaq.com/articles/the-first-tradable-cannabis-etf-has-now-lost-half-its-value-2019-09-28 | nan | nan | According to estimates from Wall Street, as well as an assortment of independent reports, marijuana is the greatest growth trend to come along since sliced bread. Having generated just shy of $11 billion in global sales last year, worldwide revenue is forecast to catapult to between $50 billion and $200 billion by the ... | Since August 2016, Aurora Cannabis (NYSE: ACB) has made well over one dozen acquisitions. In California, residents in certain locales could be shouldering a tax burden of up to 45%, which doesn't take into account ancillary fees, such as laboratory testing and compliance costs that are also being built into cannabis pr... | Since August 2016, Aurora Cannabis (NYSE: ACB) has made well over one dozen acquisitions. Supply and tax issues throughout North America The 800-pound gorilla in the room is that the North American marijuana industry has been contending with supply issues and/or tax problems galore. Take Canopy Growth (NYSE: CGC), the ... | Since August 2016, Aurora Cannabis (NYSE: ACB) has made well over one dozen acquisitions. The first-ever marijuana ETF is plunging Since hitting an all-time intraday high of $20.86 on Oct. 16, 2018, the day prior to the launch of recreational pot products in Canada, the first exchange-traded fund focused on cannabis, w... | Since August 2016, Aurora Cannabis (NYSE: ACB) has made well over one dozen acquisitions. In the fiscal first quarter, Canopy Growth reported minimal sequential cannabis sales growth, but delivered a charge-laden net loss of 1.28 billion Canadian dollars. Marijuana stocks may very well be in that downtrend right now. |
38096.0 | 2019-09-27 00:00:00 UTC | Interesting ACB Put And Call Options For November 15th | ACB | https://www.nasdaq.com/articles/interesting-acb-put-and-call-options-for-november-15th-2019-09-27 | nan | nan | Investors in Aurora Cannabis Inc (Symbol: ACB) saw new options begin trading this week, for the November 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACB options chain for the new November 15th contracts and identified one put and one call contract of particular interest.... | Of course, a lot of upside could potentially be left on the table if ACB shares really soar, which is why looking at the trailing twelve month trading history for Aurora Cannabis Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACB's trailing twelve month trading history, w... | Below is a chart showing ACB's trailing twelve month trading history, with the $7.00 strike highlighted in red: Considering the fact that the $7.00 strike represents an approximate 49% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibi... | Below is a chart showing ACB's trailing twelve month trading history, with the $7.00 strike highlighted in red: Considering the fact that the $7.00 strike represents an approximate 49% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibi... | At Stock Options Channel, our YieldBoost formula has looked up and down the ACB options chain for the new November 15th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACB's trailing twelve month trading history, with the $7.00 strike highlighted in red: Consideri... |
38097.0 | 2019-09-27 00:00:00 UTC | In the Marijuana Industry, Cash Isn't King | ACB | https://www.nasdaq.com/articles/in-the-marijuana-industry-cash-isnt-king-2019-09-27 | nan | nan | The legal marijuana industry is expanding at an incredible pace. It's no secret that the demand is there, given the tens of billions of dollars in global sales that have been ongoing for decades in the black market.
However, we're beginning to see these sales shift to legal channels in Canada and select U.S. states. In... | As of the end of June, Aurora Cannabis (NYSE: ACB) had more than 360 million Canadian dollars in cash, marketable securities, and restricted cash on its balance sheet. The same could be said for Cronos Group (NASDAQ: CRON), which netted itself a healthy $1.8 billion payday from tobacco giant Altria in exchange for a 45... | As of the end of June, Aurora Cannabis (NYSE: ACB) had more than 360 million Canadian dollars in cash, marketable securities, and restricted cash on its balance sheet. Thankfully, a few brand-name pot stocks have landed major equity investments and are sitting on a veritable war chest of cash. Inclusive of capital rais... | As of the end of June, Aurora Cannabis (NYSE: ACB) had more than 360 million Canadian dollars in cash, marketable securities, and restricted cash on its balance sheet. These cannabis stocks are rolling in the green Between October 2017 and November 2018, the largest marijuana stock in the world by market cap, Canopy Gr... | As of the end of June, Aurora Cannabis (NYSE: ACB) had more than 360 million Canadian dollars in cash, marketable securities, and restricted cash on its balance sheet. As an added bonus, investors may also view this cash as something of a downside buffer to these stocks. For starters, pot stocks that have built up sign... |
38098.0 | 2019-09-27 00:00:00 UTC | Forget Aurora Cannabis, Aphria Is a Better Marijuana Stock | ACB | https://www.nasdaq.com/articles/forget-aurora-cannabis-aphria-is-a-better-marijuana-stock-2019-09-27 | nan | nan | Aurora Cannabis (NYSE: ACB) ranks as the biggest cannabis producer in the world when it comes to production capacity. It claims the highest market share in the important German medical marijuana market and the second-highest share in the Canadian adult-use recreational market. Aurora's market cap of $4.8 billion puts i... | Aurora Cannabis (NYSE: ACB) ranks as the biggest cannabis producer in the world when it comes to production capacity. Sure, the company's solid bottom-line performance stemmed from its acquisition earlier this year of German medical cannabis and pharmaceutical distributor CC Pharma. I'd argue that Canopy Growth and Cro... | Aurora Cannabis (NYSE: ACB) ranks as the biggest cannabis producer in the world when it comes to production capacity. It claims the highest market share in the important German medical marijuana market and the second-highest share in the Canadian adult-use recreational market. It's open to an equity investment by a big... | Aurora Cannabis (NYSE: ACB) ranks as the biggest cannabis producer in the world when it comes to production capacity. Forget Aurora Cannabis, here are three reasons why Aphria (NYSE: APHA) is a better marijuana stock. It's a better bargain than Aurora Another reason why Aphria is a better marijuana stock than Aurora is... | Aurora Cannabis (NYSE: ACB) ranks as the biggest cannabis producer in the world when it comes to production capacity. But a profit is a profit. One drawback to using trailing-12-month P/S ratios, though, is that they don't address the prospects of future growth. |
38099.0 | 2019-09-26 00:00:00 UTC | 7 Marijuana Stocks With Critical Levels to Watch | ACB | https://www.nasdaq.com/articles/7-marijuana-stocks-with-critical-levels-to-watch-2019-09-26 | nan | nan | [Editor’s note: This story will be updated each week with new stocks and analysis. Please check back often for Mark’s latest take on marijuana stocks.]
Technical analysis has a bad reputation. This is unfortunate, but probably well deserved. Most of the research that I see, especially technical analysis of marijuana st... | Aurora Cannabis Inc (ACB) Aurora Cannabis Inc (NYSE:) is a Canadian based company that grows are sells medical marijuana, indoor cultivation systems, and hemp related food products. After a weak earnings report and some analyst downgrades ACB stock has been in a freefall over the past three weeks. ACB is oversold so th... | Aurora Cannabis Inc (ACB) Aurora Cannabis Inc (NYSE:) is a Canadian based company that grows are sells medical marijuana, indoor cultivation systems, and hemp related food products. After a weak earnings report and some analyst downgrades ACB stock has been in a freefall over the past three weeks. ACB is oversold so th... | Aurora Cannabis Inc (ACB) Aurora Cannabis Inc (NYSE:) is a Canadian based company that grows are sells medical marijuana, indoor cultivation systems, and hemp related food products. After a weak earnings report and some analyst downgrades ACB stock has been in a freefall over the past three weeks. ACB is oversold so th... | Aurora Cannabis Inc (ACB) Aurora Cannabis Inc (NYSE:) is a Canadian based company that grows are sells medical marijuana, indoor cultivation systems, and hemp related food products. After a weak earnings report and some analyst downgrades ACB stock has been in a freefall over the past three weeks. ACB is oversold so th... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.